{"DataElement":{"publicId":"3474984","version":"2","preferredName":"Clinical Study Protocol Stratification Factors COGC Protocol Stratum Type","preferredDefinition":"information related to the protocol stratification factors._COGC protocol stratification factors.","longName":"Stratum_COGC","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2200967","version":"1","preferredName":"Clinical Study Protocol Stratification Factors","preferredDefinition":"information related to the protocol stratification factors.","longName":"CSPROT_STRATFACTOR","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2176994","version":"1","preferredName":"Protocol","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"Protocol","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AC7-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2200965","version":"1","preferredName":"Stratification Factors","preferredDefinition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","longName":"Stratification Factors","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Stratification Factors","conceptCode":"C16153","definition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F16D5628-C598-64AB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-10","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F16D5628-C59E-64AB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3474967","version":"1","preferredName":"COGC Protocol Stratum Type","preferredDefinition":"COGC protocol stratification factors.","longName":"3474967v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"160","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"ADVL1217 Stratum 1","valueDescription":"Patients with newly diagnosed brainstem gliomas.","ValueMeaning":{"publicId":"3655789","version":"1","preferredName":"Patients with newly diagnosed brainstem gliomas.","longName":"3655789","preferredDefinition":"ADVL1217 Stratum 1: Patients with newly diagnosed brainstem gliomas.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D40EE2ED-50CF-22F8-E040-BB89AD4338F7","latestVersionIndicator":"Yes","beginDate":"2013-01-24","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-01-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"D40EE2ED-50E8-22F8-E040-BB89AD4338F7","beginDate":"2013-01-24","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-01-24","modifiedBy":"ONEDATA","dateModified":"2013-01-24","deletedIndicator":"No"},{"value":"ADVL1111 Part A2","valueDescription":"Part A2: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3489437","version":"1","preferredName":"Part A2: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement","longName":"3489437","preferredDefinition":"ADVL1111 Part A2: Part A2: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C300DD68-C256-61B3-E040-BB89AD4343C8","latestVersionIndicator":"Yes","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C300DD68-C26F-61B3-E040-BB89AD4343C8","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"ONEDATA","dateModified":"2012-06-21","deletedIndicator":"No"},{"value":"ADVL1111 Part A1","valueDescription":"Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3489438","version":"1","preferredName":"Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","longName":"3489438","preferredDefinition":"ADVL1111 Part A1: Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C300DD68-C279-61B3-E040-BB89AD4343C8","latestVersionIndicator":"Yes","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C300DD68-C292-61B3-E040-BB89AD4343C8","beginDate":"2012-06-21","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-21","modifiedBy":"ONEDATA","dateModified":"2012-06-21","deletedIndicator":"No"},{"value":"ADVL1212 Part B2","valueDescription":"Part B2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","ValueMeaning":{"publicId":"3474968","version":"1","preferredName":"Part B2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","longName":"3474968","preferredDefinition":"ADVL1212 Part B2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3E0E-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-3E27-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part B1","valueDescription":"Part B1: Solid Tumor or ALCL WITHOUT BM Involve","ValueMeaning":{"publicId":"3474969","version":"1","preferredName":"Part B1: Solid Tumor or ALCL WITHOUT BM Involve","longName":"3474969","preferredDefinition":"ADVL1212 Part B1: Solid Tumor or ALCL WITHOUT BM Involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3E31-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-3E4A-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1212 Part A1","valueDescription":"Part A1: Solid Tumor or ALCL WITHOUT BM Involve","ValueMeaning":{"publicId":"3474971","version":"1","preferredName":"Part A1: Solid Tumor or ALCL WITHOUT BM Involve","longName":"3474971","preferredDefinition":"ADVL1212 Part A1: Solid Tumor or ALCL WITHOUT BM Involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3E77-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1BEC699-3E90-9F9F-E040-BB89AD430971","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"ONEDATA","dateModified":"2012-06-05","deletedIndicator":"No"},{"value":"ADVL1213 Part A1a","valueDescription":"Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3510545","version":"1","preferredName":"Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITHOUT bone marrow involvement","longName":"3510545","preferredDefinition":"Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3DE4990-4B6C-AE0B-E040-BB89AD43748C","latestVersionIndicator":"Yes","beginDate":"2012-07-02","endDate":null,"createdBy":"GEORGIEB","dateCreated":"2012-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3DE4990-4B85-AE0B-E040-BB89AD43748C","beginDate":"2012-06-15","endDate":null,"createdBy":"GEORGIEB","dateCreated":"2012-07-02","modifiedBy":"ONEDATA","dateModified":"2012-07-02","deletedIndicator":"No"},{"value":"ADVL1213 Part A1b","valueDescription":"Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3510546","version":"1","preferredName":"Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement","longName":"3510546","preferredDefinition":"Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3DE4990-4B92-AE0B-E040-BB89AD43748C","latestVersionIndicator":"Yes","beginDate":"2012-07-02","endDate":null,"createdBy":"GEORGIEB","dateCreated":"2012-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3DE4990-4BAB-AE0B-E040-BB89AD43748C","beginDate":"2012-06-15","endDate":null,"createdBy":"GEORGIEB","dateCreated":"2012-07-02","modifiedBy":"ONEDATA","dateModified":"2012-07-02","deletedIndicator":"No"},{"value":"ADVL1214 Part A2","valueDescription":"Part A2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITH or WITHOUT BM Involv","ValueMeaning":{"publicId":"3534477","version":"1","preferredName":"Part A2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITH or WITHOUT BM Involv","longName":"3534477","preferredDefinition":"ADVL1214 Part A2: Part A2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITH or WITHOUT BM Involv","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5877BBD-14D0-2D22-E040-BB89AD437941","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5877BBD-14E9-2D22-E040-BB89AD437941","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"ADVL1214 Part A1","valueDescription":"Part A1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors.WITHOUT BM Involv","ValueMeaning":{"publicId":"3534478","version":"1","preferredName":"Part A1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors.WITHOUT BM Involv","longName":"3534478","preferredDefinition":"ADVL1214 Part A1: Part A1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors.WITHOUT BM Involv","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5877BBD-14F3-2D22-E040-BB89AD437941","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5877BBD-150C-2D22-E040-BB89AD437941","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"ADVL1211 Part B","valueDescription":"Part B: Patients with medullary thyroid cancer (MTC), WITH or WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3534479","version":"1","preferredName":"Part B: Patients with medullary thyroid cancer (MTC), WITH or WITHOUT bone marrow involvement","longName":"3534479","preferredDefinition":"ADVL1211 Part B: Part B: Patients with medullary thyroid cancer (MTC), WITH or WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5877BBD-1516-2D22-E040-BB89AD437941","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5877BBD-152F-2D22-E040-BB89AD437941","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"ADVL1211 Part A2","valueDescription":"Part A2: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3534480","version":"1","preferredName":"Part A2: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement","longName":"3534480","preferredDefinition":"ADVL1211 Part A2: Part A2: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5877BBD-1539-2D22-E040-BB89AD437941","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5877BBD-1551-2D22-E040-BB89AD437941","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"ADVL1211 Part A1","valueDescription":"Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3534481","version":"1","preferredName":"Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","longName":"3534481","preferredDefinition":"ADVL1211 Part A1: Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5877BBD-155C-2D22-E040-BB89AD437941","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C5877BBD-1574-2D22-E040-BB89AD437941","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-07-23","modifiedBy":"ONEDATA","dateModified":"2012-07-23","deletedIndicator":"No"},{"value":"AHOD1221 PartA1","valueDescription":"Part A1: Phase I dose finding component: Patients with relapsed/refractory Hodgkin Lymphoma; WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3625162","version":"1","preferredName":"Part A1: Phase I dose finding component: Patients with relapsed/refractory Hodgkin Lymphoma; WITHOUT bone marrow involvement","longName":"3625162","preferredDefinition":"AHOD1221 PartA1: Part A1: Phase I dose finding component: Patients with relapsed/refractory Hodgkin Lymphoma; WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDDA19C1-3169-1B9C-E040-BB89AD432B82","latestVersionIndicator":"Yes","beginDate":"2012-11-06","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-11-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDDA19C1-3182-1B9C-E040-BB89AD432B82","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-11-06","modifiedBy":"ONEDATA","dateModified":"2012-11-06","deletedIndicator":"No"},{"value":"AHOD1221 PartA2","valueDescription":"Part A2: Phase I dose finding component: Patients with relapsed/refractory Hodgkin Lymphoma; WITH or WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3625163","version":"1","preferredName":"Part A2: Phase I dose finding component: Patients with relapsed/refractory Hodgkin Lymphoma; WITH or WITHOUT bone marrow involvement","longName":"3625163","preferredDefinition":"AHOD1221 PartA2: Part A2: Phase I dose finding component: Patients with relapsed/refractory Hodgkin Lymphoma; WITH or WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CDDA19C1-318F-1B9C-E040-BB89AD432B82","latestVersionIndicator":"Yes","beginDate":"2012-11-06","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-11-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CDDA19C1-31A8-1B9C-E040-BB89AD432B82","beginDate":"2012-07-23","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-11-06","modifiedBy":"ONEDATA","dateModified":"2012-11-06","deletedIndicator":"No"},{"value":"ADVL1213 Part A1b","valueDescription":"Patients with relapse or refractory solid tumors excluding CNS WITH or WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3479489","version":"1","preferredName":"Patients with relapse or refractory solid tumors excluding CNS WITH or WITHOUT bone marrow involvement","longName":"3479489","preferredDefinition":"ADVL1213 Part A1b: Patients with relapse or refractory solid tumors excluding CNS WITH or WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C284C068-95D6-A53E-E040-BB89AD433683","latestVersionIndicator":"Yes","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C284C068-95EF-A53E-E040-BB89AD433683","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"GEORGIEB","dateModified":"2012-07-02","deletedIndicator":"No"},{"value":"ADVL1213 Part A1a","valueDescription":"Patients with relapse or refractory solid tumors excluding CNS WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3479490","version":"1","preferredName":"Patients with relapse or refractory solid tumors excluding CNS WITHOUT bone marrow involvement","longName":"3479490","preferredDefinition":"ADVL1213 Part A1a: Patients with relapse or refractory solid tumors excluding CNS WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C284C068-95F9-A53E-E040-BB89AD433683","latestVersionIndicator":"Yes","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C284C068-9612-A53E-E040-BB89AD433683","beginDate":"2012-06-15","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-15","modifiedBy":"GEORGIEB","dateModified":"2012-07-02","deletedIndicator":"No"},{"value":"ADVL1212 Part A2","valueDescription":"Part A2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","ValueMeaning":{"publicId":"3475566","version":"1","preferredName":"Part A2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","longName":"3475566","preferredDefinition":"ADVL1212 Part A2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1E80FC9-B751-A009-E040-BB89AD430688","latestVersionIndicator":"Yes","beginDate":"2012-06-07","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1E80FC9-B76A-A009-E040-BB89AD430688","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-07","modifiedBy":"ONEDATA","dateModified":"2012-06-07","deletedIndicator":"No"},{"value":"ADVL1312 Part A1","valueDescription":"Part A1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITHOUT BM Involvement","ValueMeaning":{"publicId":"3726904","version":"1","preferredName":"Part A1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITHOUT BM Involvement","longName":"3726904","preferredDefinition":"ADVL1312 Part A1: Part A1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITHOUT BM Involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA311F5B-42E9-1336-E040-BB89AD4335DC","latestVersionIndicator":"Yes","beginDate":"2013-04-12","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA311F5B-4302-1336-E040-BB89AD4335DC","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-12","modifiedBy":"ONEDATA","dateModified":"2013-04-12","deletedIndicator":"No"},{"value":"ADVL1312 Part A2","valueDescription":"Part A2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITH/WITHOUT BM Involvement","ValueMeaning":{"publicId":"3726905","version":"1","preferredName":"Part A2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITH/WITHOUT BM Involvement","longName":"3726905","preferredDefinition":"ADVL1312 Part A2: Part A2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors WITH/WITHOUT BM Involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA311F5B-430C-1336-E040-BB89AD4335DC","latestVersionIndicator":"Yes","beginDate":"2013-04-12","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","id":"DA311F5B-4325-1336-E040-BB89AD4335DC","beginDate":"2013-04-11","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-04-12","modifiedBy":"ONEDATA","dateModified":"2013-04-12","deletedIndicator":"No"},{"value":"ADVL1111 Part B2","valueDescription":"Part B: PK COHORT POWDER SPRINKLED ON FOOD. Patients with relapsed or refractory solid tumors, including CNS; < 12 years of age","ValueMeaning":{"publicId":"3733131","version":"1","preferredName":"Part B: PK COHORT POWDER SPRINKLED ON FOOD. Patients with relapsed or refractory solid tumors, including CNS; < 12 years of age","longName":"3733131","preferredDefinition":"ADVL1111 Part B2: Part B: PK COHORT POWDER SPRINKLED ON FOOD. Patients with relapsed or refractory solid tumors, including CNS; < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB4BB0BB-CA94-ECD2-E040-BB89AD4358BF","latestVersionIndicator":"Yes","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB4BB0BB-CAAD-ECD2-E040-BB89AD4358BF","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"ONEDATA","dateModified":"2013-04-26","deletedIndicator":"No"},{"value":"ADVL1111 Part B1","valueDescription":"Part B: PK COHORT POWDER SPRINKLED ON FOOD. Patients with relapsed or refractory solid tumors, including CNS; >= 12 years of age","ValueMeaning":{"publicId":"3733132","version":"1","preferredName":"Part B: PK COHORT POWDER SPRINKLED ON FOOD. Patients with relapsed or refractory solid tumors, including CNS; >= 12 years of age","longName":"3733132","preferredDefinition":"ADVL1111 Part B1: Part B: PK COHORT POWDER SPRINKLED ON FOOD. Patients with relapsed or refractory solid tumors, including CNS; >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB4BB0BB-CAB7-ECD2-E040-BB89AD4358BF","latestVersionIndicator":"Yes","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB4BB0BB-CAD0-ECD2-E040-BB89AD4358BF","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"ONEDATA","dateModified":"2013-04-26","deletedIndicator":"No"},{"value":"ADVL1111 Part A PK","valueDescription":"Part A: PK EXPANSION COHORT. Patients with relapsed or refractory solid tumors, including CNS; < 12 years of age","ValueMeaning":{"publicId":"3733133","version":"1","preferredName":"Part A: PK EXPANSION COHORT. Patients with relapsed or refractory solid tumors, including CNS; < 12 years of age","longName":"3733133","preferredDefinition":"ADVL1111 Part A PK: Part A: PK EXPANSION COHORT. Patients with relapsed or refractory solid tumors, including CNS; < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB4BB0BB-CADA-ECD2-E040-BB89AD4358BF","latestVersionIndicator":"Yes","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB4BB0BB-CAF3-ECD2-E040-BB89AD4358BF","beginDate":"2013-04-26","endDate":null,"createdBy":"BEELEST","dateCreated":"2013-04-26","modifiedBy":"ONEDATA","dateModified":"2013-04-26","deletedIndicator":"No"},{"value":"ADVL1211 PK Part 1","valueDescription":"Part 1 PK Cohort: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement; >= 12 years of age.","ValueMeaning":{"publicId":"3895249","version":"1","preferredName":"Part 1 PK Cohort: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement; >= 12 years of age.","longName":"3895249","preferredDefinition":"ADVL1211 PK Cohort Part 1: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement; >= 12 years of age.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E632EFFE-A1C1-FCA2-E040-BB89AD434A5F","latestVersionIndicator":"Yes","beginDate":"2013-09-12","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2013-09-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E632EFFE-A1DA-FCA2-E040-BB89AD434A5F","beginDate":"2013-09-11","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2013-09-12","modifiedBy":"ONEDATA","dateModified":"2013-09-12","deletedIndicator":"No"},{"value":"ADVL1211 PK Part 2","valueDescription":"Part 2 PK Cohort: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement; < 12 years of age.","ValueMeaning":{"publicId":"3895250","version":"1","preferredName":"Part 2 PK Cohort: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement; < 12 years of age.","longName":"3895250","preferredDefinition":"ADVL1211 PK Cohort Part 2: Patients with relapsed or refractory solid tumors, including CNS; WITH or WITHOUT bone marrow involvement; < 12 years of age.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E632EFFE-A1E4-FCA2-E040-BB89AD434A5F","latestVersionIndicator":"Yes","beginDate":"2013-09-12","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2013-09-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E632EFFE-A1FD-FCA2-E040-BB89AD434A5F","beginDate":"2013-09-11","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2013-09-12","modifiedBy":"ONEDATA","dateModified":"2013-09-12","deletedIndicator":"No"},{"value":"ADVL1315 Part A2","valueDescription":"Part A2: Patients with refractory or recurrent solid tumors, excluding CNS tumors; WITH OR WITHOUT bone marrow involvement.","ValueMeaning":{"publicId":"4355849","version":"1","preferredName":"Part A2: Patients with refractory or recurrent solid tumors, excluding CNS tumors; WITH OR WITHOUT bone marrow involvement.","longName":"4355849","preferredDefinition":"ADVL1315 Part A2: Part A2: Patients with refractory or recurrent solid tumors, excluding CNS tumors; WITH OR WITHOUT bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB8273CD-38F8-65FF-E040-BB89AD432EA7","latestVersionIndicator":"Yes","beginDate":"2014-06-10","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB8273CD-3911-65FF-E040-BB89AD432EA7","beginDate":"2014-06-10","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-06-10","modifiedBy":"ONEDATA","dateModified":"2014-06-10","deletedIndicator":"No"},{"value":"ADVL1315 Part A1","valueDescription":"Part A1: Patients with refractory or recurrent solid tumors, excluding CNS tumors; WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"4355850","version":"1","preferredName":"Part A1: Patients with refractory or recurrent solid tumors, excluding CNS tumors; WITHOUT bone marrow involvement","longName":"4355850","preferredDefinition":"ADVL1315 Part A1: Part A1: Patients with refractory or recurrent solid tumors, excluding CNS tumors; WITHOUT bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB8273CD-391B-65FF-E040-BB89AD432EA7","latestVersionIndicator":"Yes","beginDate":"2014-06-10","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB8273CD-3934-65FF-E040-BB89AD432EA7","beginDate":"2014-06-10","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-06-10","modifiedBy":"ONEDATA","dateModified":"2014-06-10","deletedIndicator":"No"},{"value":"ADVL1314 Part A2","valueDescription":"Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement > 6 months and < 12 months of age","ValueMeaning":{"publicId":"4331091","version":"1","preferredName":"Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement > 6 months and < 12 months of age","longName":"4331091","preferredDefinition":"ADVL1314 Part A2: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement > 6 months and < 12 months of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA15FA5C-F7BF-D8BE-E040-BB89AD430542","latestVersionIndicator":"Yes","beginDate":"2014-05-23","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA15FA5C-F7D8-D8BE-E040-BB89AD430542","beginDate":"2014-02-20","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-05-23","modifiedBy":"ONEDATA","dateModified":"2014-05-23","deletedIndicator":"No"},{"value":"ADVL1314 Part A1","valueDescription":"Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement >= 12 months and < 18 years of age","ValueMeaning":{"publicId":"4335787","version":"1","preferredName":"Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement >= 12 months and < 18 years of age","longName":"4335787","preferredDefinition":"ADVL1314 Part A1: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement >= 12 months and < 18 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA668F67-FA3C-586F-E040-BB89AD437CD1","latestVersionIndicator":"Yes","beginDate":"2014-05-27","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA668F67-FA55-586F-E040-BB89AD437CD1","beginDate":"2014-02-20","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-05-27","modifiedBy":"ONEDATA","dateModified":"2014-05-27","deletedIndicator":"No"},{"value":"ADVL1211 PK2 Part 2","valueDescription":"PK2 Part 2 Cohort: Patients with relapsed or refractory solid tumors (excluding medullary thyroid cancer) including CNS; WITH or  WITHOUT bone marrow involvement; < 12 years of age","ValueMeaning":{"publicId":"4258611","version":"1","preferredName":"PK2 Part 2 Cohort: Patients with relapsed or refractory solid tumors (excluding medullary thyroid cancer) including CNS; WITH or  WITHOUT bone marrow involvement; < 12 years of age","longName":"4258611","preferredDefinition":"ADVL1211 PK2 Part 2 Cohort: Patients with relapsed or refractory solid tumors (excluding medullary thyroid cancer) including CNS; WITH or  WITHOUT bone marrow involvement; < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5B3EB5F-2939-C06F-E040-BB89AD43563E","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B3EB5F-2952-C06F-E040-BB89AD43563E","beginDate":"2014-03-28","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"ADVL1211 PK2 Part 1","valueDescription":"PK2 Part 1 Cohort: Patients with relapsed or refractory solid tumors (excluding medullary thyroid cancer) including CNS; WITH or WITHOUT bone marrow involvement; >= 12 years of age","ValueMeaning":{"publicId":"4258612","version":"1","preferredName":"PK2 Part 1 Cohort: Patients with relapsed or refractory solid tumors (excluding medullary thyroid cancer) including CNS; WITH or WITHOUT bone marrow involvement; >= 12 years of age","longName":"4258612","preferredDefinition":"ADVL1211 PK2 Part 1 Cohort: Patients with relapsed or refractory solid tumors (excluding medullary thyroid cancer) including CNS; WITH or WITHOUT bone marrow involvement; >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5B3EB5F-295C-C06F-E040-BB89AD43563E","latestVersionIndicator":"Yes","beginDate":"2014-03-28","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5B3EB5F-2975-C06F-E040-BB89AD43563E","beginDate":"2014-03-28","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-03-28","modifiedBy":"ONEDATA","dateModified":"2014-03-28","deletedIndicator":"No"},{"value":"ADVL1314 Stratum 1","valueDescription":"Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement","ValueMeaning":{"publicId":"4168130","version":"1","preferredName":"Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement","longName":"4168130","preferredDefinition":"ADVL1314 Stratum 1: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DD1A4C-4CFB-F249-E040-BB89AD430B39","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2DD1A4C-4D14-F249-E040-BB89AD430B39","beginDate":"2014-02-20","endDate":null,"createdBy":"BEELEST","dateCreated":"2014-02-20","modifiedBy":"MATTHEWK","dateModified":"2014-05-23","deletedIndicator":"No"},{"value":"ADVL1411 Part A1","valueDescription":"Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"3953991","version":"1","preferredName":"Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","longName":"3953991","preferredDefinition":"ADVL1411 Part A1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB8FCDF3-AE2D-EE55-E040-BB89AD4317D8","latestVersionIndicator":"Yes","beginDate":"2013-11-19","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2013-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-5254-5BF5-E040-BB89AD4357DA","beginDate":"2013-11-18","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1411 Part A2","valueDescription":"Part A2: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET; WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"4179131","version":"1","preferredName":"Part A2: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET; WITHOUT bone marrow involvement","longName":"4179131","preferredDefinition":"ADVL1411 Part A2: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET; WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F356588E-525E-5BF5-E040-BB89AD4357DA","latestVersionIndicator":"Yes","beginDate":"2014-02-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F356588E-5277-5BF5-E040-BB89AD4357DA","beginDate":"2013-11-18","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-02-26","modifiedBy":"ONEDATA","dateModified":"2014-02-26","deletedIndicator":"No"},{"value":"ADVL1213 PK Part 2","valueDescription":"PK Part 2: Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement < 12 years of age","ValueMeaning":{"publicId":"4474348","version":"1","preferredName":"PK Part 2: Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement < 12 years of age","longName":"4474348","preferredDefinition":"ADVL1213 PK Part 2: Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0232063C-6539-5431-E050-BB89AD432D09","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-09-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0232063C-6552-5431-E050-BB89AD432D09","beginDate":"2014-09-03","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-09-03","modifiedBy":"ONEDATA","dateModified":"2014-09-03","deletedIndicator":"No"},{"value":"ADVL1213 PK Part 1","valueDescription":"PK Part 1: Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement >= 12 years of age","ValueMeaning":{"publicId":"4474349","version":"1","preferredName":"PK Part 1: Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement >= 12 years of age","longName":"4474349","preferredDefinition":"ADVL1213 PK Part 1:  Patients with relapse or refractory solid tumors or lymphoma, excluding CNS WITH or WITHOUT bone marrow involvement >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0232063C-655C-5431-E050-BB89AD432D09","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-09-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0232063C-6575-5431-E050-BB89AD432D09","beginDate":"2014-09-03","endDate":null,"createdBy":"MATTHEWK","dateCreated":"2014-09-03","modifiedBy":"ONEDATA","dateModified":"2014-09-03","deletedIndicator":"No"},{"value":"ADVL1412 Part A1","valueDescription":"Part A1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, without bone marrow involvement","ValueMeaning":{"publicId":"4682153","version":"1","preferredName":"Part A1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, without bone marrow involvement","longName":"4682153","preferredDefinition":"ADVL1412 Part A1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-3666-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-367E-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part A2","valueDescription":"Part A2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement","ValueMeaning":{"publicId":"4682154","version":"1","preferredName":"Part A2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement","longName":"4682154","preferredDefinition":"ADVL1412 Part A2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-3689-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-36A1-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part B1","valueDescription":"Part B1: Patients with relapsed or refractory neuroblastoma","ValueMeaning":{"publicId":"4682155","version":"1","preferredName":"Part B1: Patients with relapsed or refractory neuroblastoma","longName":"4682155","preferredDefinition":"ADVL1412 Part B1: Patients with relapsed or refractory neuroblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-36AC-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-36C4-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part B2","valueDescription":"Part B2: Patients with relapsed or refractory osteosarcoma","ValueMeaning":{"publicId":"4682156","version":"1","preferredName":"Part B2: Patients with relapsed or refractory osteosarcoma","longName":"4682156","preferredDefinition":"ADVL1412 Part B2: Patients with relapsed or refractory osteosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-36CF-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-36E7-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part B3","valueDescription":"Part B3: Patients with relapsed or refractory rhabdomyosarcoma","ValueMeaning":{"publicId":"4682157","version":"1","preferredName":"Part B3: Patients with relapsed or refractory rhabdomyosarcoma","longName":"4682157","preferredDefinition":"ADVL1412 Part B3: Patients with relapsed or refractory rhabdomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-36F2-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-370A-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part B4","valueDescription":"Part B4: Patients with relapsed or refractory Ewing Sarcoma or Peripheral PNET","ValueMeaning":{"publicId":"4682158","version":"1","preferredName":"Part B4: Patients with relapsed or refractory Ewing Sarcoma or Peripheral PNET","longName":"4682158","preferredDefinition":"ADVL1412 Part B4: Patients with relapsed or refractory Ewing Sarcoma or Peripheral PNET","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-3715-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-372D-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part B5","valueDescription":"Part B5: Patients with relapsed or refractory Hodgkin Lymphoma","ValueMeaning":{"publicId":"4682159","version":"1","preferredName":"Part B5: Patients with relapsed or refractory Hodgkin Lymphoma","longName":"4682159","preferredDefinition":"ADVL1412 Part B5: Patients with relapsed or refractory Hodgkin Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-3738-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-3750-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part B6","valueDescription":"Part B6: Patients with relapsed or refractory Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"4682160","version":"1","preferredName":"Part B6: Patients with relapsed or refractory Non-Hodgkin Lymphoma","longName":"4682160","preferredDefinition":"ADVL1412 Part B6: Patients with relapsed or refractory Non-Hodgkin Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-375B-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-3773-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part C1","valueDescription":"Part C1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, without bone marrow involvement","ValueMeaning":{"publicId":"4682161","version":"1","preferredName":"Part C1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, without bone marrow involvement","longName":"4682161","preferredDefinition":"ADVL1412 Part C1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-377E-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-3796-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 Part C2","valueDescription":"Part C2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement","ValueMeaning":{"publicId":"4682162","version":"1","preferredName":"Part C2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement","longName":"4682162","preferredDefinition":"ADVL1412 Part C2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-37A1-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-37B9-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 PK Part A1","valueDescription":"PK Part A1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, >= 12 years of age","ValueMeaning":{"publicId":"4682163","version":"1","preferredName":"PK Part A1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, >= 12 years of age","longName":"4682163","preferredDefinition":"ADVL1412 PK Part A1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-37C4-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-37DC-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 PK Part A2","valueDescription":"PK Part A2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, < 12 years of age","ValueMeaning":{"publicId":"4682164","version":"1","preferredName":"PK Part A2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, < 12 years of age","longName":"4682164","preferredDefinition":"ADVL1412 PK Part A2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-37E7-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-37FF-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 PK Part C1","valueDescription":"PK Part C1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, >= 12 years of age","ValueMeaning":{"publicId":"4682165","version":"1","preferredName":"PK Part C1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, >= 12 years of age","longName":"4682165","preferredDefinition":"ADVL1412 PK Part C1: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-380A-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-3822-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"ADVL1412 PK Part C2","valueDescription":"PK Part C2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, < 12 years of age","ValueMeaning":{"publicId":"4682166","version":"1","preferredName":"PK Part C2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, < 12 years of age","longName":"4682166","preferredDefinition":"ADVL1412 PK Part C2: Patients with recurrent or refractory solid tumors, excluding CNS tumors, with or without bone marrow involvement, < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-382D-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D9795AD-3845-01BE-E050-BB89AD43364B","beginDate":"2015-01-07","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-01-26","modifiedBy":"ONEDATA","dateModified":"2015-01-26","deletedIndicator":"No"},{"value":"AHOD1221 Part B","valueDescription":"Part B: Patients with Hodgkin lymphoma (HL)","ValueMeaning":{"publicId":"4683988","version":"1","preferredName":"Part B: Patients with Hodgkin lymphoma (HL)","longName":"4683988","preferredDefinition":"Part B: Patients with Hodgkin lymphoma (HL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0DA6F9CA-6690-761C-E050-BB89AD434926","latestVersionIndicator":"Yes","beginDate":"2015-01-27","endDate":null,"createdBy":"WANGC","dateCreated":"2015-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DA65529-501B-DC99-E050-BB89AD430196","beginDate":"2015-01-27","endDate":null,"createdBy":"WANGC","dateCreated":"2015-01-27","modifiedBy":"ONEDATA","dateModified":"2015-01-27","deletedIndicator":"No"},{"value":"ADVL1212 Part C2","valueDescription":"Part C2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","ValueMeaning":{"publicId":"4566631","version":"1","preferredName":"Part C2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","longName":"4566631","preferredDefinition":"ADVL1212 Part C2: Solid Tumor or ALCL WITH/WITHOUT BM Involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06984E4C-362C-365C-E050-BB89AD432188","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06984E4C-3645-365C-E050-BB89AD432188","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"ADVL1212 Part C1","valueDescription":"Part C1: Solid Tumor or ALCL WITHOUT BM Involve","ValueMeaning":{"publicId":"4566632","version":"1","preferredName":"Part C1: Solid Tumor or ALCL WITHOUT BM Involve","longName":"4566632","preferredDefinition":"ADVL1212 Part C1: Solid Tumor or ALCL WITHOUT BM Involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06984E4C-364F-365C-E050-BB89AD432188","latestVersionIndicator":"Yes","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"06984E4C-3668-365C-E050-BB89AD432188","beginDate":"2014-10-29","endDate":null,"createdBy":"ZORINR","dateCreated":"2014-10-29","modifiedBy":"ONEDATA","dateModified":"2014-10-29","deletedIndicator":"No"},{"value":"ADVL1414 Part A2","valueDescription":"Part A2: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, WITH or WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"4747531","version":"1","preferredName":"Part A2: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, WITH or WITHOUT bone marrow involvement","longName":"4747531","preferredDefinition":"ADVL1414 Part A2: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, WITH or WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"119859AC-DCF3-BE92-E050-BB89AD430DDA","latestVersionIndicator":"Yes","beginDate":"2015-03-18","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"119859AC-DD0C-BE92-E050-BB89AD430DDA","beginDate":"2015-03-18","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-18","modifiedBy":"ONEDATA","dateModified":"2015-03-18","deletedIndicator":"No"},{"value":"ADVL1414 Part A1","valueDescription":"Part A1: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, WITHOUT bone marrow involvement","ValueMeaning":{"publicId":"4747532","version":"1","preferredName":"Part A1: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, WITHOUT bone marrow involvement","longName":"4747532","preferredDefinition":"ADVL1414 Part A1: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors, WITHOUT bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"119859AC-DD16-BE92-E050-BB89AD430DDA","latestVersionIndicator":"Yes","beginDate":"2015-03-18","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"119859AC-DD2F-BE92-E050-BB89AD430DDA","beginDate":"2015-03-18","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-03-18","modifiedBy":"ONEDATA","dateModified":"2015-03-18","deletedIndicator":"No"},{"value":"ADVL1412 Part B7","valueDescription":"Part B7: Patients with unresectable, metastatic, relapsed or refractory melanoma","ValueMeaning":{"publicId":"4924311","version":"1","preferredName":"Part B7: Patients with unresectable, metastatic, relapsed or refractory melanoma","longName":"4924311","preferredDefinition":"ADVL1412 Part B7: Patients with unresectable, metastatic, relapsed or refractory melanoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1BF553C4-8BDD-387A-E050-BB89AD4341B6","latestVersionIndicator":"Yes","beginDate":"2015-07-28","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-07-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1BF553C4-8BF6-387A-E050-BB89AD4341B6","beginDate":"2015-07-28","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-07-28","modifiedBy":"ONEDATA","dateModified":"2015-07-28","deletedIndicator":"No"},{"value":"ADVL1315 PK Part 2","valueDescription":"PK Part 2: Patients with refractory or recurrent solid tumors, excluding CNS tumors < 12 years of age","ValueMeaning":{"publicId":"4786480","version":"1","preferredName":"PK Part 2: Patients with refractory or recurrent solid tumors, excluding CNS tumors < 12 years of age","longName":"4786480","preferredDefinition":"ADVL1315 PK Part 2: PK Part 2: Patients with refractory or recurrent solid tumors, excluding CNS tumors < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"13409C17-2156-0EF1-E050-BB89AD4340DF","latestVersionIndicator":"Yes","beginDate":"2015-04-08","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"13409C17-216F-0EF1-E050-BB89AD4340DF","beginDate":"2015-04-08","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-04-08","modifiedBy":"ONEDATA","dateModified":"2015-04-08","deletedIndicator":"No"},{"value":"ADVL1315 PK Part 1","valueDescription":"PK Part 1: Patients with refractory or recurrent solid tumors, excluding CNS tumors >= 12 years of age","ValueMeaning":{"publicId":"4786481","version":"1","preferredName":"PK Part 1: Patients with refractory or recurrent solid tumors, excluding CNS tumors >= 12 years of age","longName":"4786481","preferredDefinition":"ADVL1315 PK Part 1: PK Part 1: Patients with refractory or recurrent solid tumors, excluding CNS tumors >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"13409C17-2179-0EF1-E050-BB89AD4340DF","latestVersionIndicator":"Yes","beginDate":"2015-04-08","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"13409C17-2192-0EF1-E050-BB89AD4340DF","beginDate":"2015-04-08","endDate":null,"createdBy":"ZORINR","dateCreated":"2015-04-08","modifiedBy":"ONEDATA","dateModified":"2015-04-08","deletedIndicator":"No"},{"value":"ADVL1314 PK Part 1","valueDescription":"PK Part 1: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, w/o bone marrow involvement >= 12 yrs and < 18 yrs of age","ValueMeaning":{"publicId":"4811632","version":"1","preferredName":"PK Part 1: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, w/o bone marrow involvement >= 12 yrs and < 18 yrs of age","longName":"4811632","preferredDefinition":"ADVL1314 PK Part 1: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, w/o bone marrow involvement >= 12 yrs and < 18 yrs of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"156C534A-5091-07A8-E050-BB89AD431D0F","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-05-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"156C534A-50AA-07A8-E050-BB89AD431D0F","beginDate":"2015-05-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-05-06","modifiedBy":"ONEDATA","dateModified":"2015-05-06","deletedIndicator":"No"},{"value":"ADVL1314 PK Part 2","valueDescription":"PK Part 2: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, w/o bone marrow involvement >= 12 months and < 12 yrs of age","ValueMeaning":{"publicId":"4811631","version":"1","preferredName":"PK Part 2: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, w/o bone marrow involvement >= 12 months and < 12 yrs of age","longName":"4811631","preferredDefinition":"ADVL1314 PK Part 2: Patients with refractory or recurrent solid tumors or lymphomas, excluding CNS tumors, w/o bone marrow involvement >= 12 months and < 12 yrs of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"156C534A-506E-07A8-E050-BB89AD431D0F","latestVersionIndicator":"Yes","beginDate":"2015-05-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-05-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"156C534A-5087-07A8-E050-BB89AD431D0F","beginDate":"2015-05-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-05-06","modifiedBy":"ONEDATA","dateModified":"2015-05-06","deletedIndicator":"No"},{"value":"ADVL1416 Part B","valueDescription":"Part B: Patients with recurrent or refactory CNS tumors","ValueMeaning":{"publicId":"4809965","version":"1","preferredName":"Part B: Patients with recurrent or refactory CNS tumors","longName":"4809965","preferredDefinition":"ADVL1416 Part B: Patients with recurrent or refactory CNS tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1546B3B7-6502-CDEB-E050-BB89AD434043","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1546B3B7-651B-CDEB-E050-BB89AD434043","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"ADVL1416 Part A2","valueDescription":"Part A2: Patients with recurrent or refactory solid tumors, excluding CNS tumors, with or without bone marrow involvement","ValueMeaning":{"publicId":"4809966","version":"1","preferredName":"Part A2: Patients with recurrent or refactory solid tumors, excluding CNS tumors, with or without bone marrow involvement","longName":"4809966","preferredDefinition":"ADVL1416 Part A2: Patients with recurrent or refactory solid tumors, excluding CNS tumors, with or without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1546B3B7-6525-CDEB-E050-BB89AD434043","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1546B3B7-653E-CDEB-E050-BB89AD434043","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"ADVL1416 Part A1","valueDescription":"Part A1: Patients with recurrent or refactory solid tumors, excluding CNS tumors, without bone marrow involvement","ValueMeaning":{"publicId":"4809967","version":"1","preferredName":"Part A1: Patients with recurrent or refactory solid tumors, excluding CNS tumors, without bone marrow involvement","longName":"4809967","preferredDefinition":"ADVL1416 Part A1: Patients with recurrent or refactory solid tumors, excluding CNS tumors, without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1546B3B7-6548-CDEB-E050-BB89AD434043","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1546B3B7-6561-CDEB-E050-BB89AD434043","beginDate":"2015-05-04","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-05-04","modifiedBy":"ONEDATA","dateModified":"2015-05-04","deletedIndicator":"No"},{"value":"ADVL1212 Part D PK Part 2","valueDescription":"Part D PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","ValueMeaning":{"publicId":"5133254","version":"1","preferredName":"Part D PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","longName":"5133254","preferredDefinition":"ADVL1212 Part D PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C8B370A-476A-1ADC-E050-BB89AD430EE8","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C8B370A-4783-1ADC-E050-BB89AD430EE8","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"ADVL1212 Part D PK Part 1","valueDescription":"Part D PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12  years of age","ValueMeaning":{"publicId":"5133255","version":"1","preferredName":"Part D PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12  years of age","longName":"5133255","preferredDefinition":"ADVL1212 Part D PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12  years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C8B370A-478D-1ADC-E050-BB89AD430EE8","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C8B370A-47A6-1ADC-E050-BB89AD430EE8","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"ADVL1212 PK Part 2","valueDescription":"PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","ValueMeaning":{"publicId":"5023671","version":"1","preferredName":"PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","longName":"5023671","preferredDefinition":"ADVL1212 PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"206F0978-89DC-A171-E050-BB89AD435FCD","latestVersionIndicator":"Yes","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"206F0978-89F5-A171-E050-BB89AD435FCD","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"ONEDATA","dateModified":"2015-09-23","deletedIndicator":"No"},{"value":"ADVL1212 PK Part 1","valueDescription":"PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12 years of age","ValueMeaning":{"publicId":"5023672","version":"1","preferredName":"PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12 years of age","longName":"5023672","preferredDefinition":"ADVL1212 PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"206F0978-89FF-A171-E050-BB89AD435FCD","latestVersionIndicator":"Yes","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"206F0978-8A18-A171-E050-BB89AD435FCD","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"ONEDATA","dateModified":"2015-09-23","deletedIndicator":"No"},{"value":"ADVL1412 Part B8","valueDescription":"Part B8: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion)","ValueMeaning":{"publicId":"5094451","version":"1","preferredName":"Part B8: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion)","longName":"5094451","preferredDefinition":"ADVL1412 Part B8: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2793DD5F-C745-2149-E050-BB89AD430592","latestVersionIndicator":"Yes","beginDate":"2015-12-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-12-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2793DD5F-C75E-2149-E050-BB89AD430592","beginDate":"2015-12-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2015-12-23","modifiedBy":"ONEDATA","dateModified":"2015-12-23","deletedIndicator":"No"},{"value":"ADVL1212 Part D2","valueDescription":"Part D2: Solid Tumor or ALCL WITH/WITHOUT BM involve","ValueMeaning":{"publicId":"5133252","version":"1","preferredName":"Part D2: Solid Tumor or ALCL WITH/WITHOUT BM involve","longName":"5133252","preferredDefinition":"ADVL1212 Part D2: Solid Tumor or ALCL WITH/WITHOUT BM involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C8AE6B4-2DB0-5A2B-E050-BB89AD430A93","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C8AE6B4-2DC9-5A2B-E050-BB89AD430A93","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"ADVL1212 Part D1","valueDescription":"Part D1: Solid Tumor or ALCL WITHOUT BM involve","ValueMeaning":{"publicId":"5133253","version":"1","preferredName":"Part D1: Solid Tumor or ALCL WITHOUT BM involve","longName":"5133253","preferredDefinition":"ADVL1212 Part D1: Solid Tumor or ALCL WITHOUT BM involve","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C8AE6B4-2DD3-5A2B-E050-BB89AD430A93","latestVersionIndicator":"Yes","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C8AE6B4-2DEC-5A2B-E050-BB89AD430A93","beginDate":"2016-02-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2016-02-24","modifiedBy":"ONEDATA","dateModified":"2016-02-24","deletedIndicator":"No"},{"value":"ADVL1411 Part B","valueDescription":"Part B: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET","ValueMeaning":{"publicId":"5148861","version":"1","preferredName":"Part B: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET","longName":"5148861","preferredDefinition":"ADVL1411 Part B: Patients with relapsed or refractory Ewing sarcoma or peripheral PNET","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D28A8CC-D18A-B21F-E050-BB89AD43607F","latestVersionIndicator":"Yes","beginDate":"2016-03-03","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-03-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D28A8CC-D1A3-B21F-E050-BB89AD43607F","beginDate":"2016-03-03","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-03-03","modifiedBy":"ONEDATA","dateModified":"2016-03-03","deletedIndicator":"No"},{"value":"ADVL1411 PK Part 2","valueDescription":"PK Part 2: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement < 12 years of age","ValueMeaning":{"publicId":"5148862","version":"1","preferredName":"PK Part 2: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement < 12 years of age","longName":"5148862","preferredDefinition":"ADVL1411 PK Part 2: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D28A8CC-D1AD-B21F-E050-BB89AD43607F","latestVersionIndicator":"Yes","beginDate":"2016-03-03","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-03-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D28A8CC-D1C6-B21F-E050-BB89AD43607F","beginDate":"2016-03-03","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-03-03","modifiedBy":"ONEDATA","dateModified":"2016-03-03","deletedIndicator":"No"},{"value":"ADVL1411 PK Part 1","valueDescription":"PK Part 1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement >= 12 years of age","ValueMeaning":{"publicId":"5148863","version":"1","preferredName":"PK Part 1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement >= 12 years of age","longName":"5148863","preferredDefinition":"ADVL1411 PK Part 1: Patients with relapsed or refractory solid tumors, including CNS; WITHOUT bone marrow involvement >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D28A8CC-D1D0-B21F-E050-BB89AD43607F","latestVersionIndicator":"Yes","beginDate":"2016-03-03","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-03-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2D28A8CC-D1E9-B21F-E050-BB89AD43607F","beginDate":"2016-03-03","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-03-03","modifiedBy":"ONEDATA","dateModified":"2016-03-03","deletedIndicator":"No"},{"value":"ADVL1212 Part C PK Part 1","valueDescription":"Part C PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12 years of age","ValueMeaning":{"publicId":"5023703","version":"1","preferredName":"Part C PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12 years of age","longName":"5023703","preferredDefinition":"ADVL1212 Part C PK Part 1: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"206F94B0-BBA8-3AD7-E050-BB89AD4370BC","latestVersionIndicator":"Yes","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"206F94B0-BBC1-3AD7-E050-BB89AD4370BC","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"ONEDATA","dateModified":"2015-09-23","deletedIndicator":"No"},{"value":"ADVL1212 Part C PK Part 2","valueDescription":"Part C PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","ValueMeaning":{"publicId":"5023704","version":"1","preferredName":"Part C PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","longName":"5023704","preferredDefinition":"ADVL1212 Part C PK Part 2: Patients with relapsed/refractory solid tumors or ALCL without heme restrictions < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"206F94B0-BBCB-3AD7-E050-BB89AD4370BC","latestVersionIndicator":"Yes","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"206F94B0-BBE4-3AD7-E050-BB89AD4370BC","beginDate":"2015-09-23","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-09-23","modifiedBy":"ONEDATA","dateModified":"2015-09-23","deletedIndicator":"No"},{"value":"ADVL1312 Part C","valueDescription":"Part C: Patients with relapsed or refractory medulloblastoma or CNS PNET","ValueMeaning":{"publicId":"5351675","version":"1","preferredName":"Part C: Patients with relapsed or refractory medulloblastoma or CNS PNET","longName":"5351675","preferredDefinition":"ADVL1312 Part C: Patients with relapsed or refractory medulloblastoma or CNS PNET","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38010ED6-A265-3197-E050-BB89AD432F50","latestVersionIndicator":"Yes","beginDate":"2016-07-19","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"38010ED6-A27E-3197-E050-BB89AD432F50","beginDate":"2016-07-19","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-19","modifiedBy":"ONEDATA","dateModified":"2016-07-19","deletedIndicator":"No"},{"value":"ADVL1312 Part B","valueDescription":"Part B: Patients with relapsed or refractory neuroblastoma","ValueMeaning":{"publicId":"5351676","version":"1","preferredName":"Part B: Patients with relapsed or refractory neuroblastoma","longName":"5351676","preferredDefinition":"ADVL1312 Part B: Patients with relapsed or refractory neuroblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38010ED6-A288-3197-E050-BB89AD432F50","latestVersionIndicator":"Yes","beginDate":"2016-07-19","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"38010ED6-A2A1-3197-E050-BB89AD432F50","beginDate":"2016-07-19","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-19","modifiedBy":"ONEDATA","dateModified":"2016-07-19","deletedIndicator":"No"},{"value":"APEC1621 Stratum 1","valueDescription":"Stratum 1: Patients with relapse or refractory solid tumors incl. CNS tumors, lymphoma, and histocytosis","ValueMeaning":{"publicId":"5358659","version":"1","preferredName":"Stratum 1: Patients with relapse or refractory solid tumors incl. CNS tumors, lymphoma, and histocytosis","longName":"5358659","preferredDefinition":"APEC1621 Stratum 1: Patients with relapse or refractory solid tumors incl. CNS tumors, lymphoma, and histocytosis","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"388D1060-B3C2-4E10-E050-BB89AD434D6C","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A2AAE55-04D5-7178-E053-F662850A0E7E","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-07","modifiedBy":"ONEDATA","dateModified":"2017-03-07","deletedIndicator":"No"},{"value":"APEC1621A Stratum 1","valueDescription":"Stratum 1: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621A","ValueMeaning":{"publicId":"5361063","version":"1","preferredName":"Stratum 1: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621A","longName":"5361063","preferredDefinition":"APEC1621A Stratum 1: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"388DB710-0750-A715-E050-BB89AD4336C5","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"388DB710-0769-A715-E050-BB89AD4336C5","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-26","modifiedBy":"ONEDATA","dateModified":"2016-07-26","deletedIndicator":"No"},{"value":"APEC1621D Stratum 1","valueDescription":"Stratum 1: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621D","ValueMeaning":{"publicId":"5361155","version":"1","preferredName":"Stratum 1: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621D","longName":"5361155","preferredDefinition":"APEC1621D Stratum 1: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"388E25E0-1EBE-D31C-E050-BB89AD4348FE","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"388E25E0-1ED7-D31C-E050-BB89AD4348FE","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-26","modifiedBy":"ONEDATA","dateModified":"2016-07-26","deletedIndicator":"No"},{"value":"ADVL1513 Stratum 1","valueDescription":"Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors.","ValueMeaning":{"publicId":"5341433","version":"1","preferredName":"Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors.","longName":"5341433","preferredDefinition":"ADVL1513 Stratum 1: Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37618252-A263-DCCB-E050-BB89AD437307","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"37618252-A27C-DCCB-E050-BB89AD437307","beginDate":"2016-07-11","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-07-11","modifiedBy":"ONEDATA","dateModified":"2016-07-11","deletedIndicator":"No"},{"value":"ADVL1515 Part A2","valueDescription":"Part A2: Patients with recurrent or refractory solid tumors, including CNS tumors, with or without bone marrow involvement","ValueMeaning":{"publicId":"5343213","version":"1","preferredName":"Part A2: Patients with recurrent or refractory solid tumors, including CNS tumors, with or without bone marrow involvement","longName":"5343213","preferredDefinition":"ADVL1515 Part A2: Patients with recurrent or refractory solid tumors, including CNS tumors, with or without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3775B4FB-6A6D-50C9-E050-BB89AD433716","latestVersionIndicator":"Yes","beginDate":"2016-07-12","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3775B4FB-6A86-50C9-E050-BB89AD433716","beginDate":"2016-07-12","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-12","modifiedBy":"ONEDATA","dateModified":"2016-07-12","deletedIndicator":"No"},{"value":"ADVL1515 Part A1","valueDescription":"Part A1: Patients with recurrent or refractory solid tumors, including CNS tumors, without bone marrow involvement","ValueMeaning":{"publicId":"5343214","version":"1","preferredName":"Part A1: Patients with recurrent or refractory solid tumors, including CNS tumors, without bone marrow involvement","longName":"5343214","preferredDefinition":"ADVL1515 Part A1: Patients with recurrent or refractory solid tumors, including CNS tumors, without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3775B4FB-6A90-50C9-E050-BB89AD433716","latestVersionIndicator":"Yes","beginDate":"2016-07-12","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3775B4FB-6AA9-50C9-E050-BB89AD433716","beginDate":"2016-07-12","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-12","modifiedBy":"ONEDATA","dateModified":"2016-07-12","deletedIndicator":"No"},{"value":"ACCL15N1CD Healthcare Provider","valueDescription":"Healthcare Provider","ValueMeaning":{"publicId":"2576285","version":"1","preferredName":"Healthcare Provider","longName":"2576285","preferredDefinition":"Healthcare Provider","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F70A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2005-09-19","modifiedBy":"COOPERM","dateModified":"2005-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A218355-AAE0-1A7F-E050-BB89AD431D8C","beginDate":"2016-08-15","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-08-15","modifiedBy":"ONEDATA","dateModified":"2016-08-15","deletedIndicator":"No"},{"value":"ACCL15N1CD Patient","valueDescription":"Patient","ValueMeaning":{"publicId":"2569281","version":"1","preferredName":"Patient","longName":"2569281v1.00","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DBAE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-04-15","modifiedBy":"KUMMEROA","dateModified":"2024-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A218355-AAF4-1A7F-E050-BB89AD431D8C","beginDate":"2016-08-15","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-08-15","modifiedBy":"ONEDATA","dateModified":"2016-08-15","deletedIndicator":"No"},{"value":"APEC1621D Stratum 3c","valueDescription":"Stratum 3c: Patients with relapsed or refractory histology specific solid tumors, without biomarker MATCH to APEC1621D","ValueMeaning":{"publicId":"5365120","version":"1","preferredName":"Stratum 3c: Patients with relapsed or refractory histology specific solid tumors, without biomarker MATCH to APEC1621D","longName":"5365120","preferredDefinition":"APEC1621D Stratum 3c: Patients with relapsed or refractory histology specific solid tumors, without biomarker MATCH to APEC1621D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38A1D83B-2C35-397D-E050-BB89AD431221","latestVersionIndicator":"Yes","beginDate":"2016-07-27","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"38A1D83B-2C4E-397D-E050-BB89AD431221","beginDate":"2016-07-27","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-27","modifiedBy":"ONEDATA","dateModified":"2016-07-27","deletedIndicator":"No"},{"value":"APEC1621D Stratum 2c","valueDescription":"Stratum 2c: Patients with relapsed or refractory histology specific solid tumors, without biomarker MATCH to APEC1621D","ValueMeaning":{"publicId":"5365121","version":"1","preferredName":"Stratum 2c: Patients with relapsed or refractory histology specific solid tumors, without biomarker MATCH to APEC1621D","longName":"5365121","preferredDefinition":"APEC1621D Stratum 2c: Patients with relapsed or refractory histology specific solid tumors, without biomarker MATCH to APEC1621D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38A1D83B-2C58-397D-E050-BB89AD431221","latestVersionIndicator":"Yes","beginDate":"2016-07-27","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"38A1D83B-2C71-397D-E050-BB89AD431221","beginDate":"2016-07-27","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-27","modifiedBy":"ONEDATA","dateModified":"2016-07-27","deletedIndicator":"No"},{"value":"APEC1621A Stratum 3c","valueDescription":"Stratum 3c: Patients with relapse or refractory, histology specific solid tumors, with biomarker positive MATCH to APEC1621A","ValueMeaning":{"publicId":"5365122","version":"1","preferredName":"Stratum 3c: Patients with relapse or refractory, histology specific solid tumors, with biomarker positive MATCH to APEC1621A","longName":"5365122","preferredDefinition":"APEC1621A Stratum 3c: Patients with relapse or refractory, histology specific solid tumors, with biomarker positive MATCH to APEC1621A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38A1D83B-2C7B-397D-E050-BB89AD431221","latestVersionIndicator":"Yes","beginDate":"2016-07-27","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"38A1D83B-2C94-397D-E050-BB89AD431221","beginDate":"2016-07-27","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-27","modifiedBy":"ONEDATA","dateModified":"2016-07-27","deletedIndicator":"No"},{"value":"APEC1621A Stratum 2c","valueDescription":"Stratum 2c: Patients with relapse or refractory, histology specific solid tumors, with biomarker positive MATCH to APEC1621A","ValueMeaning":{"publicId":"5361060","version":"1","preferredName":"Stratum 2c: Patients with relapse or refractory, histology specific solid tumors, with biomarker positive MATCH to APEC1621A","longName":"5361060","preferredDefinition":"APEC1621A Stratum 2c: Patients with relapse or refractory, histology specific solid tumors, with biomarker positive MATCH to APEC1621A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"388DB710-06E7-A715-E050-BB89AD4336C5","latestVersionIndicator":"Yes","beginDate":"2016-07-26","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"38A1D83B-2CA8-397D-E050-BB89AD431221","beginDate":"2016-07-27","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-07-27","modifiedBy":"ONEDATA","dateModified":"2016-07-27","deletedIndicator":"No"},{"value":"ADVL1611 PK Part 1","valueDescription":"PK Part 1: Patients with relapsed or refractory AML >= 12 years of age","ValueMeaning":{"publicId":"5253351","version":"1","preferredName":"PK Part 1: Patients with relapsed or refractory AML >= 12 years of age","longName":"5253351","preferredDefinition":"ADVL1611 PK Part 1: Patients with relapsed or refractory AML >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3220927F-8F8C-0AB6-E050-BB89AD43100A","latestVersionIndicator":"Yes","beginDate":"2016-05-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3220927F-8FA4-0AB6-E050-BB89AD43100A","beginDate":"2016-03-30","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"ADVL1611 PK Part 2","valueDescription":"PK Part 2: Patients with relapsed or refractory AML < 12 years of age","ValueMeaning":{"publicId":"5253352","version":"1","preferredName":"PK Part 2: Patients with relapsed or refractory AML < 12 years of age","longName":"5253352","preferredDefinition":"ADVL1611 PK Part 2: Patients with relapsed or refractory AML < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3220927F-8FAF-0AB6-E050-BB89AD43100A","latestVersionIndicator":"Yes","beginDate":"2016-05-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3220927F-8FC7-0AB6-E050-BB89AD43100A","beginDate":"2016-03-30","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"ADVL1611 Stratum 1","valueDescription":"Patients with relapsed or refractory AML","ValueMeaning":{"publicId":"5253353","version":"1","preferredName":"Patients with relapsed or refractory AML","longName":"5253353","preferredDefinition":"ADVL1611 Stratum 1: Patients with relapsed or refractory AML","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3220927F-8FD3-0AB6-E050-BB89AD43100A","latestVersionIndicator":"Yes","beginDate":"2016-05-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3220927F-8FEB-0AB6-E050-BB89AD43100A","beginDate":"2016-05-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2016-05-05","modifiedBy":"ONEDATA","dateModified":"2016-05-05","deletedIndicator":"No"},{"value":"ADVL1312 PK Part 1","valueDescription":"PK Part 1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors greater than or equal to 12 years of age","ValueMeaning":{"publicId":"5379529","version":"1","preferredName":"PK Part 1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors greater than or equal to 12 years of age","longName":"5379529","preferredDefinition":"ADVL1312 PK Part 1: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors greater than or equal to 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3941454E-85D8-28E1-E050-BB89AD43742A","latestVersionIndicator":"Yes","beginDate":"2016-08-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-08-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3942443B-05C9-190F-E050-BB89AD431D29","beginDate":"2016-08-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-08-04","modifiedBy":"ONEDATA","dateModified":"2016-08-04","deletedIndicator":"No"},{"value":"ADVL1312 PK Part 2","valueDescription":"PK Part 2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors less than 12 years of age","ValueMeaning":{"publicId":"5379527","version":"1","preferredName":"PK Part 2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors less than 12 years of age","longName":"5379527","preferredDefinition":"ADVL1312 PK Part 2: Patients with relapsed or refractory solid tumors, including patients with primary or metastatic CNS tumors less than 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3941454E-85B5-28E1-E050-BB89AD43742A","latestVersionIndicator":"Yes","beginDate":"2016-08-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-08-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3942443B-05B5-190F-E050-BB89AD431D29","beginDate":"2016-08-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-08-04","modifiedBy":"ONEDATA","dateModified":"2016-08-04","deletedIndicator":"No"},{"value":"ADVL1412 Part D6","valueDescription":"Part D6: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion)","ValueMeaning":{"publicId":"5429073","version":"1","preferredName":"Part D6: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion)","longName":"5429073","preferredDefinition":"ADVL1412 Part D6: Patients with relapsed or refractory neuroblastoma (MIBG evaluable disease without RECIST measurable lesion)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AC017E9-8D5B-D457-E050-BB89AD435EE3","latestVersionIndicator":"Yes","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3AC017E9-8D74-D457-E050-BB89AD435EE3","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"ONEDATA","dateModified":"2016-08-23","deletedIndicator":"No"},{"value":"ADVL1412 Part D5","valueDescription":"Part D5: Patients with relapsed or refractory Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"5429074","version":"1","preferredName":"Part D5: Patients with relapsed or refractory Non-Hodgkin Lymphoma","longName":"5429074","preferredDefinition":"ADVL1412 Part D5: Patients with relapsed or refractory Non-Hodgkin Lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AC017E9-8D7E-D457-E050-BB89AD435EE3","latestVersionIndicator":"Yes","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3AC017E9-8D97-D457-E050-BB89AD435EE3","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"ONEDATA","dateModified":"2016-08-23","deletedIndicator":"No"},{"value":"ADVL1412 Part D4","valueDescription":"Part D4: Patients with relapsed or refractory Ewing Sarcoma or Peripheral PNET","ValueMeaning":{"publicId":"5429075","version":"1","preferredName":"Part D4: Patients with relapsed or refractory Ewing Sarcoma or Peripheral PNET","longName":"5429075","preferredDefinition":"ADVL1412 Part D4: Patients with relapsed or refractory Ewing Sarcoma or Peripheral PNET","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AC017E9-8DA1-D457-E050-BB89AD435EE3","latestVersionIndicator":"Yes","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3AC017E9-8DBA-D457-E050-BB89AD435EE3","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"ONEDATA","dateModified":"2016-08-23","deletedIndicator":"No"},{"value":"ADVL1412 Part D2","valueDescription":"Part D2: Patients with relapsed or refractory osteosarcoma","ValueMeaning":{"publicId":"5429077","version":"1","preferredName":"Part D2: Patients with relapsed or refractory osteosarcoma","longName":"5429077","preferredDefinition":"ADVL1412 Part D2: Patients with relapsed or refractory osteosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AC017E9-8DE7-D457-E050-BB89AD435EE3","latestVersionIndicator":"Yes","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3AC017E9-8E00-D457-E050-BB89AD435EE3","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"ONEDATA","dateModified":"2016-08-23","deletedIndicator":"No"},{"value":"ADVL1412 Part D1","valueDescription":"Part D1: Patients with relapsed or refractory neuroblastoma","ValueMeaning":{"publicId":"5429078","version":"1","preferredName":"Part D1: Patients with relapsed or refractory neuroblastoma","longName":"5429078","preferredDefinition":"ADVL1412 Part D1: Patients with relapsed or refractory neuroblastoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AC017E9-8E0A-D457-E050-BB89AD435EE3","latestVersionIndicator":"Yes","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3AC017E9-8E23-D457-E050-BB89AD435EE3","beginDate":"2016-08-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2016-08-23","modifiedBy":"ONEDATA","dateModified":"2016-08-23","deletedIndicator":"No"},{"value":"APEC1621D Primary Cohort B","valueDescription":"Primary Cohort B: Patients whose tumors have other PI3K/MTOR pathway activating mutations","ValueMeaning":{"publicId":"5699860","version":"1","preferredName":"Primary Cohort B: Patients whose tumors have other PI3K/MTOR pathway activating mutations","longName":"5699860","preferredDefinition":"APEC1621D Primary Cohort B: Patients whose tumors have other PI3K/MTOR pathway activating mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3D7BAC-05B5-30F8-E053-F662850A494F","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A3D7BAC-05CE-30F8-E053-F662850A494F","beginDate":"2017-03-08","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-08","modifiedBy":"ONEDATA","dateModified":"2017-03-08","deletedIndicator":"No"},{"value":"APEC1621D Primary Cohort A","valueDescription":"Primary Cohort A: Patients whose tumors have TSC1 or TSC2 loss of function mutations","ValueMeaning":{"publicId":"5699861","version":"1","preferredName":"Primary Cohort A: Patients whose tumors have TSC1 or TSC2 loss of function mutations","longName":"5699861","preferredDefinition":"APEC1621D Primary Cohort A: Patients whose tumors have TSC1 or TSC2 loss of function mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A3D7BAC-05D8-30F8-E053-F662850A494F","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4A3D7BAC-05F1-30F8-E053-F662850A494F","beginDate":"2017-03-08","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-08","modifiedBy":"ONEDATA","dateModified":"2017-03-08","deletedIndicator":"No"},{"value":"APEC1621D Histology BioNeg","valueDescription":"Histology BioNeg: Patients with relapse or refractory histology specific solid tumors, biomarker negative.","ValueMeaning":{"publicId":"5724491","version":"1","preferredName":"Histology BioNeg: Patients with relapse or refractory histology specific solid tumors, biomarker negative.","longName":"5724491","preferredDefinition":"APEC1621D Histology BioNeg: Patients with relapse or refractory histology specific solid tumors, biomarker negative.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B6AC12A-7181-2147-E053-F662850A0BDB","latestVersionIndicator":"Yes","beginDate":"2017-03-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4B6AC12A-719A-2147-E053-F662850A0BDB","beginDate":"2017-03-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-23","modifiedBy":"ONEDATA","dateModified":"2017-03-23","deletedIndicator":"No"},{"value":"APEC1621E Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621E","ValueMeaning":{"publicId":"5716941","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621E","longName":"5716941","preferredDefinition":"APEC1621E Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE00B1F-DE2D-06F6-E053-F662850ABC60","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4AE00B1F-DE46-06F6-E053-F662850ABC60","beginDate":"2017-03-16","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-16","modifiedBy":"ONEDATA","dateModified":"2017-03-16","deletedIndicator":"No"},{"value":"ADVL1412 Part D3","valueDescription":"Part D3: Patients with relapsed or refractory rhabdomyosarcoma","ValueMeaning":{"publicId":"5632458","version":"1","preferredName":"Part D3: Patients with relapsed or refractory rhabdomyosarcoma","longName":"5632458","preferredDefinition":"ADVL1412 Part D3: Patients with relapsed or refractory rhabdomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46C7B7EF-E0C4-21E1-E053-F662850A95EF","latestVersionIndicator":"Yes","beginDate":"2017-01-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"46C7B7EF-E0DD-21E1-E053-F662850A95EF","beginDate":"2017-01-23","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-01-23","modifiedBy":"ONEDATA","dateModified":"2017-01-23","deletedIndicator":"No"},{"value":"APEC1621C Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C","ValueMeaning":{"publicId":"5716614","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C","longName":"5716614","preferredDefinition":"APEC1621C Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4ADBA18D-D1F9-3A95-E053-F662850A162B","latestVersionIndicator":"Yes","beginDate":"2017-03-16","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4ADBA18D-D212-3A95-E053-F662850A162B","beginDate":"2017-03-16","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-03-16","modifiedBy":"ONEDATA","dateModified":"2017-03-16","deletedIndicator":"No"},{"value":"APEC1621H Dose Finding","valueDescription":"Dose Finding: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621H","ValueMeaning":{"publicId":"5873967","version":"1","preferredName":"Dose Finding: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621H","longName":"5873967","preferredDefinition":"APEC1621H Dose Finding: Dose finding for patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621H","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5218336F-5CB0-383E-E053-F662850A4DC7","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5218336F-5CC9-383E-E053-F662850A4DC7","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"APEC1621F Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621F Primary Cohort A","ValueMeaning":{"publicId":"5878706","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621F Primary Cohort A","longName":"5878706","preferredDefinition":"APEC1621F Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621F Primary Cohort A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526A9173-7901-7A0D-E053-F662850A08A2","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526A9173-791A-7A0D-E053-F662850A08A2","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"ADVL1513 PK Part 2","valueDescription":"Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors < 12 years of age","ValueMeaning":{"publicId":"5916296","version":"1","preferredName":"Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors < 12 years of age","longName":"5916296","preferredDefinition":"ADVL1513 PK Part 2: Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55535C79-E13C-740A-E053-F662850A2E98","latestVersionIndicator":"Yes","beginDate":"2017-07-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2017-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"55535C79-E155-740A-E053-F662850A2E98","beginDate":"2017-07-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2017-07-27","modifiedBy":"ONEDATA","dateModified":"2017-07-27","deletedIndicator":"No"},{"value":"ADVL1513 PK Part 1","valueDescription":"Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors >=12 years of age","ValueMeaning":{"publicId":"5916297","version":"1","preferredName":"Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors >=12 years of age","longName":"5916297","preferredDefinition":"ADVL1513 PK Part 1: Patients with recurrent or refractory solid tumors without bone marrow involvement including lymphoma and CNS tumors >=12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55535C79-E15F-740A-E053-F662850A2E98","latestVersionIndicator":"Yes","beginDate":"2017-07-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2017-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"55535C79-E178-740A-E053-F662850A2E98","beginDate":"2017-07-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2017-07-27","modifiedBy":"ONEDATA","dateModified":"2017-07-27","deletedIndicator":"No"},{"value":"APEC1621D Biomarker Neg","valueDescription":"Biomarker Neg: Patients with relapsed or refractory histology agnostic solid tumors, biomarker negative","ValueMeaning":{"publicId":"5880049","version":"1","preferredName":"Biomarker Neg: Patients with relapsed or refractory histology agnostic solid tumors, biomarker negative","longName":"5880049","preferredDefinition":"APEC1621D Biomarker Neg: Patients with relapsed or refractory histology agnostic solid tumors, biomarker negative","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-4858-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-4871-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioNeg 3","valueDescription":"Histology BioNeg 3: Patients with relapsed or refractory, histology specific solid tumor 3, biomarker negative","ValueMeaning":{"publicId":"5880050","version":"1","preferredName":"Histology BioNeg 3: Patients with relapsed or refractory, histology specific solid tumor 3, biomarker negative","longName":"5880050","preferredDefinition":"APEC1621D Histology BioNeg 3: Patients with relapsed or refractory, histology specific solid tumor 3, biomarker negative","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-487B-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-4894-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioNeg 2","valueDescription":"Histology BioNeg 2: Patients with relapsed or refractory, histology specific solid tumor 2, biomarker negative","ValueMeaning":{"publicId":"5880051","version":"1","preferredName":"Histology BioNeg 2: Patients with relapsed or refractory, histology specific solid tumor 2, biomarker negative","longName":"5880051","preferredDefinition":"APEC1621D Histology BioNeg 2: Patients with relapsed or refractory, histology specific solid tumor 2, biomarker negative","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-489E-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-48B7-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioNeg 1","valueDescription":"Histology BioNeg 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker negative","ValueMeaning":{"publicId":"5880052","version":"1","preferredName":"Histology BioNeg 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker negative","longName":"5880052","preferredDefinition":"APEC1621D Histology BioNeg 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker negative","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-48C1-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-48DA-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioPos 6","valueDescription":"Histology BioPos 6: Patients with relapsed or refractory, histology specific solid tumor 6, with biomarker positive MATCH to APEC1621D Primary Cohort B","ValueMeaning":{"publicId":"5880053","version":"1","preferredName":"Histology BioPos 6: Patients with relapsed or refractory, histology specific solid tumor 6, with biomarker positive MATCH to APEC1621D Primary Cohort B","longName":"5880053","preferredDefinition":"APEC1621D Histology BioPos 6: Patients with relapsed or refractory, histology specific solid tumor 6, with biomarker positive MATCH to APEC1621D Primary Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-48E4-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-48FD-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioPos 5","valueDescription":"Histology BioPos 5: Patients with relapsed or refractory, histology specific solid tumor 5, with biomarker positive MATCH to APEC1621D Primary Cohort B","ValueMeaning":{"publicId":"5880054","version":"1","preferredName":"Histology BioPos 5: Patients with relapsed or refractory, histology specific solid tumor 5, with biomarker positive MATCH to APEC1621D Primary Cohort B","longName":"5880054","preferredDefinition":"APEC1621D Histology BioPos 5: Patients with relapsed or refractory, histology specific solid tumor 5, with biomarker positive MATCH to APEC1621D Primary Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-4907-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-4920-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioPos 4","valueDescription":"Histology BioPos 4: Patients with relapsed or refractory, histology specific solid tumor 4, with biomarker positive MATCH to APEC1621D Primary Cohort B","ValueMeaning":{"publicId":"5880055","version":"1","preferredName":"Histology BioPos 4: Patients with relapsed or refractory, histology specific solid tumor 4, with biomarker positive MATCH to APEC1621D Primary Cohort B","longName":"5880055","preferredDefinition":"APEC1621D Histology BioPos 4: Patients with relapsed or refractory, histology specific solid tumor 4, with biomarker positive MATCH to APEC1621D Primary Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-492A-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-4943-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621D Primary Cohort A","ValueMeaning":{"publicId":"5880056","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621D Primary Cohort A","longName":"5880056","preferredDefinition":"APEC1621D Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621D Primary Cohort A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-494D-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-4966-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621D Primary Cohort A","ValueMeaning":{"publicId":"5880057","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621D Primary Cohort A","longName":"5880057","preferredDefinition":"APEC1621D Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621D Primary Cohort A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-4970-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-4989-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621D Primary Cohort A","ValueMeaning":{"publicId":"5880058","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621D Primary Cohort A","longName":"5880058","preferredDefinition":"APEC1621D Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621D Primary Cohort A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-4993-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-49AC-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Dose Finding B","valueDescription":"Dose Finding B: Dose finding for patients whose tumors have other PI3K/MTOR pathway activating mutations","ValueMeaning":{"publicId":"5880059","version":"1","preferredName":"Dose Finding B: Dose finding for patients whose tumors have other PI3K/MTOR pathway activating mutations","longName":"5880059","preferredDefinition":"APEC1621D Dose Finding B: Dose finding for patients whose tumors have other PI3K/MTOR pathway activating mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-49B6-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-49CF-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621D Dose Finding A","valueDescription":"Dose Finding A: Dose finding for patients whose tumors have TSC1 or TSC2 loss of function mutations","ValueMeaning":{"publicId":"5880060","version":"1","preferredName":"Dose Finding A: Dose finding for patients whose tumors have TSC1 or TSC2 loss of function mutations","longName":"5880060","preferredDefinition":"APEC1621D Dose Finding A: Dose finding for patients whose tumors have TSC1 or TSC2 loss of function mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527E1BA1-49D9-0DF6-E053-F662850A7ACB","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527E1BA1-49F2-0DF6-E053-F662850A7ACB","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621E Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621E","ValueMeaning":{"publicId":"5881714","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621E","longName":"5881714","preferredDefinition":"APEC1621E Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"528E9AF2-68A4-6091-E053-F662850AAB52","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"528E9AF2-68BD-6091-E053-F662850AAB52","beginDate":"2017-06-22","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-22","modifiedBy":"ONEDATA","dateModified":"2017-06-22","deletedIndicator":"No"},{"value":"APEC1621E Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621E","ValueMeaning":{"publicId":"5881713","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621E","longName":"5881713","preferredDefinition":"APEC1621E Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"528E9AF2-6881-6091-E053-F662850AAB52","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"528E9AF2-689A-6091-E053-F662850AAB52","beginDate":"2017-06-22","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-22","modifiedBy":"ONEDATA","dateModified":"2017-06-22","deletedIndicator":"No"},{"value":"APEC1621E Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621E","ValueMeaning":{"publicId":"5881715","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621E","longName":"5881715","preferredDefinition":"APEC1621E Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"528E9AF2-68C7-6091-E053-F662850AAB52","latestVersionIndicator":"Yes","beginDate":"2017-06-22","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"528E9AF2-68E0-6091-E053-F662850AAB52","beginDate":"2017-06-22","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-22","modifiedBy":"ONEDATA","dateModified":"2017-06-22","deletedIndicator":"No"},{"value":"APEC1621F Histology BioPos 4","valueDescription":"Histology BioPos 4: Patients with relapsed or refractory, histology specific solid tumor 4, with biomarker positive MATCH to APEC1621F Primary Cohort B","ValueMeaning":{"publicId":"5878712","version":"1","preferredName":"Histology BioPos 4: Patients with relapsed or refractory, histology specific solid tumor 4, with biomarker positive MATCH to APEC1621F Primary Cohort B","longName":"5878712","preferredDefinition":"APEC1621F Histology BioPos 4: Patients with relapsed or refractory, histology specific solid tumor 4, with biomarker positive MATCH to APEC1621F Primary Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5269F076-913C-5C75-E053-F662850A3E00","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5269F076-9155-5C75-E053-F662850A3E00","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"ADVL1514 Stratum 1","valueDescription":"Stratum 1: Patients with recurrent or refractory solid tumors without bone marrow involvement including CNS tumors.","ValueMeaning":{"publicId":"5806812","version":"1","preferredName":"Stratum 1: Patients with recurrent or refractory solid tumors without bone marrow involvement including CNS tumors.","longName":"5806812","preferredDefinition":"ADVL1514 Stratum 1: Patients with recurrent or refractory solid tumors without bone marrow involvement including CNS tumors.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA80CF2-C5AE-23EB-E053-F662850AE355","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2017-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EA80CF2-C5C7-23EB-E053-F662850AE355","beginDate":"2017-05-03","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2017-05-03","modifiedBy":"ONEDATA","dateModified":"2017-05-03","deletedIndicator":"No"},{"value":"APEC1621H Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621H","ValueMeaning":{"publicId":"5873970","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621H","longName":"5873970","preferredDefinition":"APEC1621H Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621H","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5217EEB7-34B7-572A-E053-F662850AC025","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5217EEB7-34D0-572A-E053-F662850AC025","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"APEC1621H Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621H","ValueMeaning":{"publicId":"5874188","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621H","longName":"5874188","preferredDefinition":"APEC1621H Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621H","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"521BD30A-5742-6CAC-E053-F662850AE85A","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"521BD30A-575B-6CAC-E053-F662850AE85A","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"ADVL1514 Stratum 2","valueDescription":"Stratum 2: Patients with recurrent or refractory solid tumors with or without bone marrow involvement including CNS tumors","ValueMeaning":{"publicId":"5808295","version":"1","preferredName":"Stratum 2: Patients with recurrent or refractory solid tumors with or without bone marrow involvement including CNS tumors","longName":"5808295","preferredDefinition":"ADVL1514 Stratum 2: Patients with recurrent or refractory solid tumors with or without bone marrow involvement including CNS tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EBCA386-A9FC-49DA-E053-F662850A586F","latestVersionIndicator":"Yes","beginDate":"2017-05-04","endDate":null,"createdBy":"BEELEST","dateCreated":"2017-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EBCA386-AA15-49DA-E053-F662850A586F","beginDate":"2017-05-04","endDate":null,"createdBy":"BEELEST","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"},{"value":"APEC1621F Primary Cohort B","valueDescription":"Primary Cohort B: Patients whose tumors have ALK missense mutations","ValueMeaning":{"publicId":"5878700","version":"1","preferredName":"Primary Cohort B: Patients whose tumors have ALK missense mutations","longName":"5878700","preferredDefinition":"APEC1621F Primary Cohort B: Patients whose tumors have ALK missense mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526AB4D1-B395-5B00-E053-F662850AA944","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526AB4D1-B3AE-5B00-E053-F662850AA944","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621F Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621F Primary Cohort A","ValueMeaning":{"publicId":"5878703","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621F Primary Cohort A","longName":"5878703","preferredDefinition":"APEC1621F Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621F Primary Cohort A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526AB4D1-B3D3-5B00-E053-F662850AA944","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526AB4D1-B3EC-5B00-E053-F662850AA944","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621F Safety Cohort A","valueDescription":"Safety Cohort A: Safety for patients whose tumors have ALK or ROS1 fusions","ValueMeaning":{"publicId":"5878640","version":"1","preferredName":"Safety Cohort A: Safety for patients whose tumors have ALK or ROS1 fusions","longName":"5878640","preferredDefinition":"APEC1621F Safety Cohort A: Safety for patients whose tumors have ALK or ROS1 fusions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526A84BF-3E55-7085-E053-F662850A28DA","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526A84BF-3E6E-7085-E053-F662850A28DA","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621G Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621G","ValueMeaning":{"publicId":"5878831","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621G","longName":"5878831","preferredDefinition":"APEC1621G Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621G","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526D0AF7-F4AD-5EE8-E053-F662850A27B5","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526D0AF7-F4C6-5EE8-E053-F662850A27B5","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621C Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621C","ValueMeaning":{"publicId":"5879969","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621C","longName":"5879969","preferredDefinition":"APEC1621C Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527CB6D2-A024-491B-E053-F662850AC3F5","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527CB6D2-A03D-491B-E053-F662850AC3F5","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621C Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621C","ValueMeaning":{"publicId":"5879971","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621C","longName":"5879971","preferredDefinition":"APEC1621C Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, with biomarker positive MATCH to APEC1621C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527CB6D2-A06A-491B-E053-F662850AC3F5","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527CB6D2-A083-491B-E053-F662850AC3F5","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"APEC1621C Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621C","ValueMeaning":{"publicId":"5879970","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621C","longName":"5879970","preferredDefinition":"APEC1621C Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621C","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"527CB6D2-A047-491B-E053-F662850AC3F5","latestVersionIndicator":"Yes","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"527CB6D2-A060-491B-E053-F662850AC3F5","beginDate":"2017-06-21","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-21","modifiedBy":"ONEDATA","dateModified":"2017-06-21","deletedIndicator":"No"},{"value":"ADVL1416 Part A PK Part 1","valueDescription":"Part A PK Part 1:  Patients with recurrent or refractory solid tumors, excluding CNS tumors >= 12 years of age","ValueMeaning":{"publicId":"5807091","version":"1","preferredName":"Part A PK Part 1:  Patients with recurrent or refractory solid tumors, excluding CNS tumors >= 12 years of age","longName":"5807091","preferredDefinition":"ADVL1416 Part A PK Part 1: Patients with recurrent or refractory solid tumors, excluding CNS tumors >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EB75034-AC28-1FA7-E053-F662850A5F6B","latestVersionIndicator":"Yes","beginDate":"2017-05-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EB75034-AC41-1FA7-E053-F662850A5F6B","beginDate":"2017-05-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"},{"value":"APEC1621H Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621H","ValueMeaning":{"publicId":"5874191","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621H","longName":"5874191","preferredDefinition":"APEC1621H Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621H","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"521BFC88-8925-6C36-E053-F662850A014F","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"521BFC88-893E-6C36-E053-F662850A014F","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"APEC1621H Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621H","ValueMeaning":{"publicId":"5874194","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621H","longName":"5874194","preferredDefinition":"APEC1621H Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621H","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"521BFC88-8963-6C36-E053-F662850A014F","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"521BFC88-897C-6C36-E053-F662850A014F","beginDate":"2017-06-16","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"APEC1621G Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621G","ValueMeaning":{"publicId":"5878834","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621G","longName":"5878834","preferredDefinition":"APEC1621G Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621G","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526CCF46-E349-6349-E053-F662850A04B6","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526CCF46-E362-6349-E053-F662850A04B6","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621SC Screening","valueDescription":"Screening: Patients with recurrent or refractory solid tumors incl. non-Hodgkin lymphomas, histiocytoses, and CNS tumors","ValueMeaning":{"publicId":"5873929","version":"1","preferredName":"Screening: Patients with recurrent or refractory solid tumors incl. non-Hodgkin lymphomas, histiocytoses, and CNS tumors","longName":"5873929","preferredDefinition":"APEC1621SC Screening: Patients with recurrent or refractory solid tumors incl. non-Hodgkin lymphomas, histiocytoses, and CNS tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5217257C-7E92-0B50-E053-F662850A5DF0","latestVersionIndicator":"Yes","beginDate":"2017-06-16","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5217257C-7EAB-0B50-E053-F662850A5DF0","beginDate":"2017-06-16","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-16","modifiedBy":"ONEDATA","dateModified":"2017-06-16","deletedIndicator":"No"},{"value":"APEC1621F Safety Cohort B","valueDescription":"Safety Cohort B: Safety for patients whose tumors have ALK missense mutations","ValueMeaning":{"publicId":"5878694","version":"1","preferredName":"Safety Cohort B: Safety for patients whose tumors have ALK missense mutations","longName":"5878694","preferredDefinition":"APEC1621F Safety Cohort B: Safety for patients whose tumors have ALK missense mutations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526A049B-AE63-7B6B-E053-F662850AFCD2","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526A049B-AE7C-7B6B-E053-F662850AFCD2","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621F Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621F Primary Cohort A","ValueMeaning":{"publicId":"5878709","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621F Primary Cohort A","longName":"5878709","preferredDefinition":"APEC1621F Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621F Primary Cohort A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526AE1D4-3807-4C40-E053-F662850A2FCC","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526AE1D4-3820-4C40-E053-F662850A2FCC","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621F Primary Cohort A","valueDescription":"Primary Cohort A: Patients whose tumors have ALK or ROS1 fusions","ValueMeaning":{"publicId":"5878697","version":"1","preferredName":"Primary Cohort A: Patients whose tumors have ALK or ROS1 fusions","longName":"5878697","preferredDefinition":"APEC1621F Primary Cohort A: Patients whose tumors have ALK or ROS1 fusions","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5269F55C-4268-6AD2-E053-F662850A4292","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5269F55C-4281-6AD2-E053-F662850A4292","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621F Histology BioPos 5","valueDescription":"Histology BioPos 5: Patients with relapsed or refractory, histology specific solid tumor 5, with biomarker positive MATCH to APEC1621F Primary Cohort B","ValueMeaning":{"publicId":"5878715","version":"1","preferredName":"Histology BioPos 5: Patients with relapsed or refractory, histology specific solid tumor 5, with biomarker positive MATCH to APEC1621F Primary Cohort B","longName":"5878715","preferredDefinition":"APEC1621F Histology BioPos 5: Patients with relapsed or refractory, histology specific solid tumor 5, with biomarker positive MATCH to APEC1621F Primary Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5269F55C-42A6-6AD2-E053-F662850A4292","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5269F55C-42BF-6AD2-E053-F662850A4292","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621F Histology BioPos 6","valueDescription":"Histology BioPos 6: Patients with relapsed or refractory, histology specific solid tumor 6, with biomarker positive MATCH to APEC1621F Primary Cohort B","ValueMeaning":{"publicId":"5878718","version":"1","preferredName":"Histology BioPos 6: Patients with relapsed or refractory, histology specific solid tumor 6, with biomarker positive MATCH to APEC1621F Primary Cohort B","longName":"5878718","preferredDefinition":"APEC1621F Histology BioPos 6: Patients with relapsed or refractory, histology specific solid tumor 6, with biomarker positive MATCH to APEC1621F Primary Cohort B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526AECB4-05BE-6173-E053-F662850AB4CF","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526AECB4-05D7-6173-E053-F662850AB4CF","beginDate":"2017-06-20","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621A Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621A","ValueMeaning":{"publicId":"5878890","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621A","longName":"5878890","preferredDefinition":"APEC1621A Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526F5A56-C8A5-052C-E053-F662850AF773","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526F5A56-C8BE-052C-E053-F662850AF773","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621A Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621A","ValueMeaning":{"publicId":"5878891","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621A","longName":"5878891","preferredDefinition":"APEC1621A Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526F5A56-C8C8-052C-E053-F662850AF773","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526F5A56-C8E1-052C-E053-F662850AF773","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621A Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621A","ValueMeaning":{"publicId":"5878892","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621A","longName":"5878892","preferredDefinition":"APEC1621A Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526F5A56-C8EB-052C-E053-F662850AF773","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526F5A56-C904-052C-E053-F662850AF773","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621A Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621A","ValueMeaning":{"publicId":"5878893","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621A","longName":"5878893","preferredDefinition":"APEC1621A Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621A","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526F5A56-C90E-052C-E053-F662850AF773","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526F5A56-C927-052C-E053-F662850AF773","beginDate":"2017-06-20","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621G Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621G","ValueMeaning":{"publicId":"5878837","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621G","longName":"5878837","preferredDefinition":"APEC1621G Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621G","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526D2D3A-CBAE-6439-E053-F662850A1835","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526D2D3A-CBC7-6439-E053-F662850A1835","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"APEC1621G Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621G","ValueMeaning":{"publicId":"5878808","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621G","longName":"5878808","preferredDefinition":"APEC1621G Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621G","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"526BCB23-F78D-3288-E053-F662850A2824","latestVersionIndicator":"Yes","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"526BCB23-F7A6-3288-E053-F662850A2824","beginDate":"2017-06-20","endDate":null,"createdBy":"SULLIVANG","dateCreated":"2017-06-20","modifiedBy":"ONEDATA","dateModified":"2017-06-20","deletedIndicator":"No"},{"value":"ADVL1416 Part A PK Part 2","valueDescription":"Part A PK Part 2: Patients with recurrent or refractory solid tumors, excluding CNS tumors < 12 years of age","ValueMeaning":{"publicId":"5807101","version":"1","preferredName":"Part A PK Part 2: Patients with recurrent or refractory solid tumors, excluding CNS tumors < 12 years of age","longName":"5807101","preferredDefinition":"ADVL1416 Part A PK Part 2: Patients with recurrent or refractory solid tumors, excluding CNS tumors < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EB78D8D-FBF3-1C7A-E053-F662850A5D3B","latestVersionIndicator":"Yes","beginDate":"2017-05-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EB78D8D-FC0C-1C7A-E053-F662850A5D3B","beginDate":"2017-05-04","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"},{"value":"ADVL1312 Part D","valueDescription":"Part D: Patients with relapsed or refractory rhabdomyosarcoma","ValueMeaning":{"publicId":"6018109","version":"1","preferredName":"Part D: Patients with relapsed or refractory rhabdomyosarcoma","longName":"6018109","preferredDefinition":"ADVL1312 Part D: Patients with relapsed or refractory rhabdomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D053BB9-FA36-4FB2-E053-F662850AF88A","latestVersionIndicator":"Yes","beginDate":"2017-11-02","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-11-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5D053BB9-FA4F-4FB2-E053-F662850AF88A","beginDate":"2017-11-02","endDate":null,"createdBy":"EDUARDOJ","dateCreated":"2017-11-02","modifiedBy":"ONEDATA","dateModified":"2017-11-02","deletedIndicator":"No"},{"value":"ACCL16N1CD Patient Stratum 3","valueDescription":"22-39 years of age","ValueMeaning":{"publicId":"6038806","version":"1","preferredName":"22-39 years of age","longName":"6038806","preferredDefinition":"ACCL16N1CD Patient Stratum 3: 22-39 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FB0FD8F-B5E2-4F61-E053-F662850A749D","latestVersionIndicator":"Yes","beginDate":"2017-12-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5FB0FD8F-B5FB-4F61-E053-F662850A749D","beginDate":"2017-12-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-12-06","modifiedBy":"ONEDATA","dateModified":"2017-12-06","deletedIndicator":"No"},{"value":"ACCL16N1CD Patient Stratum 2","valueDescription":"18-21 years of age","ValueMeaning":{"publicId":"6038807","version":"1","preferredName":"18-21 years of age","longName":"6038807","preferredDefinition":"ACCL16N1CD Patient Stratum 2: 18-21 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FB0FD8F-B605-4F61-E053-F662850A749D","latestVersionIndicator":"Yes","beginDate":"2017-12-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5FB0FD8F-B61E-4F61-E053-F662850A749D","beginDate":"2017-12-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-12-06","modifiedBy":"ONEDATA","dateModified":"2017-12-06","deletedIndicator":"No"},{"value":"ACCL16N1CD Patient Stratum 1","valueDescription":"15-17 years of age","ValueMeaning":{"publicId":"6038808","version":"1","preferredName":"15-17 years of age","longName":"6038808","preferredDefinition":"ACCL16N1CD Patient Stratum 1: 15-17 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5FB0FD8F-B628-4F61-E053-F662850A749D","latestVersionIndicator":"Yes","beginDate":"2017-12-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5FB0FD8F-B641-4F61-E053-F662850A749D","beginDate":"2017-12-06","endDate":null,"createdBy":"ROSSD","dateCreated":"2017-12-06","modifiedBy":"ONEDATA","dateModified":"2017-12-06","deletedIndicator":"No"},{"value":"APEC1621B Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621B","ValueMeaning":{"publicId":"6005951","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621B","longName":"6005951","preferredDefinition":"APEC1621B Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BEF7DF0-0F0C-079A-E053-F662850AF3AA","latestVersionIndicator":"Yes","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BEF7DF0-0F25-079A-E053-F662850AF3AA","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"ONEDATA","dateModified":"2017-10-19","deletedIndicator":"No"},{"value":"APEC1621B Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621B","ValueMeaning":{"publicId":"6005952","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621B","longName":"6005952","preferredDefinition":"APEC1621B Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BEF7DF0-0F2F-079A-E053-F662850AF3AA","latestVersionIndicator":"Yes","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BEF7DF0-0F48-079A-E053-F662850AF3AA","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"ONEDATA","dateModified":"2017-10-19","deletedIndicator":"No"},{"value":"APEC1621B Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621B","ValueMeaning":{"publicId":"6005953","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621B","longName":"6005953","preferredDefinition":"APEC1621B Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BEF7DF0-0F52-079A-E053-F662850AF3AA","latestVersionIndicator":"Yes","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BEF7DF0-0F6B-079A-E053-F662850AF3AA","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"ONEDATA","dateModified":"2017-10-19","deletedIndicator":"No"},{"value":"APEC1621B Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621B","ValueMeaning":{"publicId":"6005954","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621B","longName":"6005954","preferredDefinition":"APEC1621B Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621B","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BEF7DF0-0F75-079A-E053-F662850AF3AA","latestVersionIndicator":"Yes","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BEF7DF0-0F8E-079A-E053-F662850AF3AA","beginDate":"2017-10-19","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-10-19","modifiedBy":"ONEDATA","dateModified":"2017-10-19","deletedIndicator":"No"},{"value":"ADVL1614 Part B2","valueDescription":"Part B2: Patients with recurrent/refractory osteosarcoma, with measurable disease, >= 12 months to <= 21 years of age.","ValueMeaning":{"publicId":"6042968","version":"1","preferredName":"Part B2: Patients with recurrent/refractory osteosarcoma, with measurable disease, >= 12 months to <= 21 years of age.","longName":"6042968","preferredDefinition":"ADVL1614 Part B2: Patients with recurrent/refractory osteosarcoma, with measurable disease, >= 12 months to <= 21 years of age.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6055EEC7-F189-0CBA-E053-F662850A5EB6","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6055EEC7-F1A2-0CBA-E053-F662850A5EB6","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"ADVL1614 Part B1","valueDescription":"Part B1: Patients with recurrent/refractory osteosarcoma, with measurable disease, >= 22 years to <= 30 years of age.","ValueMeaning":{"publicId":"6042969","version":"1","preferredName":"Part B1: Patients with recurrent/refractory osteosarcoma, with measurable disease, >= 22 years to <= 30 years of age.","longName":"6042969","preferredDefinition":"ADVL1614 Part B1: Patients with recurrent/refractory osteosarcoma, with measurable disease, >= 22 years to <= 30 years of age.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6055EEC7-F1AC-0CBA-E053-F662850A5EB6","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6055EEC7-F1C4-0CBA-E053-F662850A5EB6","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"ADVL1614 Part A PK1","valueDescription":"Part A PK1: Patients with recurrent/refractory solid tumors, without heme restrictions, >= 12 years of age.","ValueMeaning":{"publicId":"6042970","version":"1","preferredName":"Part A PK1: Patients with recurrent/refractory solid tumors, without heme restrictions, >= 12 years of age.","longName":"6042970","preferredDefinition":"ADVL1614 Part A PK1: Patients with recurrent/refractory solid tumors, without heme restrictions, >= 12 years of age.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6055EEC7-F1CE-0CBA-E053-F662850A5EB6","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6055EEC7-F1E6-0CBA-E053-F662850A5EB6","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"ADVL1614 Part A PK2","valueDescription":"Part A PK2: Patients with recurrent/refractory solid tumors, without heme restriction, < 12 years of age.","ValueMeaning":{"publicId":"6042971","version":"1","preferredName":"Part A PK2: Patients with recurrent/refractory solid tumors, without heme restriction, < 12 years of age.","longName":"6042971","preferredDefinition":"ADVL1614 Part A PK2: Patients with recurrent/refractory solid tumors, without heme restriction, < 12 years of age.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6055EEC7-F1F0-0CBA-E053-F662850A5EB6","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6055EEC7-F209-0CBA-E053-F662850A5EB6","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"ADVL1615 Part A1a","valueDescription":"Part A1a: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, without bone marrow involvement","ValueMeaning":{"publicId":"5983882","version":"1","preferredName":"Part A1a: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, without bone marrow involvement","longName":"5983882","preferredDefinition":"ADVL1615 Part A1a: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A2FB6C5-9750-71BB-E053-F662850A05ED","latestVersionIndicator":"Yes","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A2FB6C5-9769-71BB-E053-F662850A05ED","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"ONEDATA","dateModified":"2017-09-27","deletedIndicator":"No"},{"value":"ADVL1615 Part A1b","valueDescription":"Part A1b: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, with or without bone marrow involvement","ValueMeaning":{"publicId":"5983885","version":"1","preferredName":"Part A1b: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, with or without bone marrow involvement","longName":"5983885","preferredDefinition":"ADVL1615 Part A1b: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, with or without bone marrow involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A2D7D14-D154-7D83-E053-F662850A1A8C","latestVersionIndicator":"Yes","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A2D7D14-D16D-7D83-E053-F662850A1A8C","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"ONEDATA","dateModified":"2017-09-27","deletedIndicator":"No"},{"value":"APEC1621I Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621I","ValueMeaning":{"publicId":"6042546","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621I","longName":"6042546","preferredDefinition":"APEC1621I Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"604DA8A7-3C6C-03F5-E053-F662850A6994","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"604DA8A7-3C85-03F5-E053-F662850A6994","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"APEC1621I Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621I","ValueMeaning":{"publicId":"6042547","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621I","longName":"6042547","preferredDefinition":"APEC1621I Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"604DA8A7-3C8F-03F5-E053-F662850A6994","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"604DA8A7-3CA8-03F5-E053-F662850A6994","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"APEC1621I Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621I","ValueMeaning":{"publicId":"6042548","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621I","longName":"6042548","preferredDefinition":"APEC1621I Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"604DA8A7-3CB2-03F5-E053-F662850A6994","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"604DA8A7-3CCB-03F5-E053-F662850A6994","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"APEC1621I Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621I","ValueMeaning":{"publicId":"6042549","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621I","longName":"6042549","preferredDefinition":"APEC1621I Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"604DA8A7-3CD5-03F5-E053-F662850A6994","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"604DA8A7-3CEE-03F5-E053-F662850A6994","beginDate":"2017-12-14","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"ADVL1615 Part A2","valueDescription":"Part A2: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, >= 6 month and < 12 months of age","ValueMeaning":{"publicId":"5983888","version":"1","preferredName":"Part A2: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, >= 6 month and < 12 months of age","longName":"5983888","preferredDefinition":"ADVL1615 Part A2: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, >= 6 month and < 12 months of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A2FC616-DE5C-5DFD-E053-F662850AE44B","latestVersionIndicator":"Yes","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A2FC616-DE75-5DFD-E053-F662850AE44B","beginDate":"2017-09-27","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-09-27","modifiedBy":"ONEDATA","dateModified":"2017-09-27","deletedIndicator":"No"},{"value":"ADVL1614 Part A1","valueDescription":"Part A1: Patients with recurrent/refractory solid tumors, measurable/evaluable disease, excluding CNS tumors, without bone marrow involvement.","ValueMeaning":{"publicId":"6042959","version":"1","preferredName":"Part A1: Patients with recurrent/refractory solid tumors, measurable/evaluable disease, excluding CNS tumors, without bone marrow involvement.","longName":"6042959","preferredDefinition":"ADVL1614 Part A1: Patients with recurrent/refractory solid tumors, measurable/evaluable disease, excluding CNS tumors, without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6054EF29-0C14-5526-E053-F662850AEA45","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6054EF29-0C2D-5526-E053-F662850AEA45","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"ADVL1614 Part A2","valueDescription":"Part A2: Patients with recurrent/refractory solid tumors, measurable/evaluable disease, excluding CNS tumors, with/without bone marrow involvement.","ValueMeaning":{"publicId":"6042962","version":"1","preferredName":"Part A2: Patients with recurrent/refractory solid tumors, measurable/evaluable disease, excluding CNS tumors, with/without bone marrow involvement.","longName":"6042962","preferredDefinition":"ADVL1614 Part A2: Patients with recurrent/refractory solid tumors, measurable/evaluable disease, excluding CNS tumors, with/without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6054EFEB-0C27-0E09-E053-F662850AE26D","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6054EFEB-0C40-0E09-E053-F662850AE26D","beginDate":"2017-12-14","endDate":null,"createdBy":"ARAGONP","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"ADVL1515 PK Part 2","valueDescription":"PK Part 2: Patients with recurrent or refractory solid tumors, including CNS tumors < 12 years of age","ValueMeaning":{"publicId":"6046525","version":"1","preferredName":"PK Part 2: Patients with recurrent or refractory solid tumors, including CNS tumors < 12 years of age","longName":"6046525","preferredDefinition":"ADVL1515 PK Part 2: Patients with recurrent or refractory solid tumors, including CNS tumors < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61CF71A2-9120-097A-E053-F662850A0648","latestVersionIndicator":"Yes","beginDate":"2018-01-02","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61CF71A2-9139-097A-E053-F662850A0648","beginDate":"2018-01-02","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"ADVL1515 PK Part 1","valueDescription":"PK Part 1: Patients with recurrent or refractory solid tumors, including CNS tumors >= 12 years of age","ValueMeaning":{"publicId":"6046526","version":"1","preferredName":"PK Part 1: Patients with recurrent or refractory solid tumors, including CNS tumors >= 12 years of age","longName":"6046526","preferredDefinition":"ADVL1515 PK Part 1: Patients with recurrent or refractory solid tumors, including CNS tumors >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61CF71A2-9143-097A-E053-F662850A0648","latestVersionIndicator":"Yes","beginDate":"2018-01-02","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"61CF71A2-915C-097A-E053-F662850A0648","beginDate":"2018-01-02","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-01-02","modifiedBy":"ONEDATA","dateModified":"2018-01-02","deletedIndicator":"No"},{"value":"ADVL1414 PK Part 1","valueDescription":"PK Part 1: Patients with relapsed/refractory solid tumors without heme restrictions >= 12 years of age","ValueMeaning":{"publicId":"6153987","version":"1","preferredName":"PK Part 1: Patients with relapsed/refractory solid tumors without heme restrictions >= 12 years of age","longName":"6153987","preferredDefinition":"ADVL1414 PK Part 1: Patients with relapsed/refractory solid tumors without heme restrictions >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68697907-2E82-35C2-E053-F662850A0DCB","latestVersionIndicator":"Yes","beginDate":"2018-03-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"68697907-2E9B-35C2-E053-F662850A0DCB","beginDate":"2018-03-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","deletedIndicator":"No"},{"value":"ADVL1414 PK Part 2","valueDescription":"PK Part 2: Patients with relapsed/refractory solid tumors without heme restrictions <12 years of age","ValueMeaning":{"publicId":"6153990","version":"1","preferredName":"PK Part 2: Patients with relapsed/refractory solid tumors without heme restrictions <12 years of age","longName":"6153990","preferredDefinition":"ADVL1414 PK Part 2: Patients with relapsed/refractory solid tumors without heme restrictions <12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"686983B8-3534-1259-E053-F662850ABBEA","latestVersionIndicator":"Yes","beginDate":"2018-03-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"686983B8-354D-1259-E053-F662850ABBEA","beginDate":"2018-03-27","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-03-27","modifiedBy":"ONEDATA","dateModified":"2018-03-27","deletedIndicator":"No"},{"value":"ADVL1712 Stratum 1","valueDescription":"Stratum 1: Patients with relapsed or refractory AML","ValueMeaning":{"publicId":"6361356","version":"1","preferredName":"Stratum 1: Patients with relapsed or refractory AML","longName":"6361356","preferredDefinition":"ADVL1712 Stratum 1: Patients with relapsed or refractory AML","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"714DB6BA-999F-690E-E053-F662850A754A","latestVersionIndicator":"Yes","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"714DB6BA-99B7-690E-E053-F662850A754A","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","deletedIndicator":"No"},{"value":"ADVL1712 PK Part 2","valueDescription":"PK Part 2: Patients with relapsed or refractory AML < 12 years of age","ValueMeaning":{"publicId":"6361354","version":"1","preferredName":"PK Part 2: Patients with relapsed or refractory AML < 12 years of age","longName":"6361354","preferredDefinition":"ADVL1712 PK Part 2: Patients with relapsed or refractory AML < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"714DB6BA-995B-690E-E053-F662850A754A","latestVersionIndicator":"Yes","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"714DB6BA-9973-690E-E053-F662850A754A","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","deletedIndicator":"No"},{"value":"ADVL1712 PK Part 1","valueDescription":"PK Part 1: Patients with relapsed or refractory AML >= 12 years of age","ValueMeaning":{"publicId":"6361355","version":"1","preferredName":"PK Part 1: Patients with relapsed or refractory AML >= 12 years of age","longName":"6361355","preferredDefinition":"ADVL1712 PK Part 1: Patients with relapsed or refractory AML >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"714DB6BA-997D-690E-E053-F662850A754A","latestVersionIndicator":"Yes","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"714DB6BA-9995-690E-E053-F662850A754A","beginDate":"2018-07-18","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-18","modifiedBy":"ONEDATA","dateModified":"2018-07-18","deletedIndicator":"No"},{"value":"ADVL1412 Part E4","valueDescription":"Part E4: Patients with relapsed or refractory Ewing Sarcoma of Peripheral PNET","ValueMeaning":{"publicId":"6345472","version":"1","preferredName":"Part E4: Patients with relapsed or refractory Ewing Sarcoma of Peripheral PNET","longName":"6345472","preferredDefinition":"ADVL1412 Part E4: Patients with relapsed or refractory Ewing Sarcoma of Peripheral PNET","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"701D4520-27CA-02E7-E053-F662850AE663","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"701D4520-27E3-02E7-E053-F662850AE663","beginDate":"2018-07-03","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","deletedIndicator":"No"},{"value":"ADVL1412 Part E3","valueDescription":"Part E3: Patients with relapsed or refractory rhabdomyosarcoma","ValueMeaning":{"publicId":"6345473","version":"1","preferredName":"Part E3: Patients with relapsed or refractory rhabdomyosarcoma","longName":"6345473","preferredDefinition":"ADVL1412 Part E3: Patients with relapsed or refractory rhabdomyosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"701D4520-27ED-02E7-E053-F662850AE663","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"701D4520-2806-02E7-E053-F662850AE663","beginDate":"2018-07-03","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-07-03","modifiedBy":"ONEDATA","dateModified":"2018-07-03","deletedIndicator":"No"},{"value":"AINV18P1 Part B","valueDescription":"Part B: Patients with recurrent or refractory B- or T-ALL/LL","ValueMeaning":{"publicId":"6303228","version":"1","preferredName":"Part B: Patients with recurrent or refractory B- or T-ALL/LL","longName":"6303228","preferredDefinition":"AINV18P1 Part B: Patients with recurrent or refractory B- or T-ALL/LL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CF8CAE2-40FB-6DF5-E053-F662850ACCB8","latestVersionIndicator":"Yes","beginDate":"2018-05-24","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF8CAE2-4114-6DF5-E053-F662850ACCB8","beginDate":"2018-05-24","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","deletedIndicator":"No"},{"value":"AINV18P1 Part A","valueDescription":"Part A: Patients with recurrent or refractory B- or T-ALL/LL","ValueMeaning":{"publicId":"6303197","version":"1","preferredName":"Part A: Patients with recurrent or refractory B- or T-ALL/LL","longName":"6303197","preferredDefinition":"AINV18P1 Part A: Patients with recurrent or refractory B- or T-ALL/LL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CF8E52F-2CC1-1DBC-E053-F662850A66F7","latestVersionIndicator":"Yes","beginDate":"2018-05-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF8E52F-2CDA-1DBC-E053-F662850A66F7","beginDate":"2018-05-24","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-05-24","modifiedBy":"ONEDATA","dateModified":"2018-05-24","deletedIndicator":"No"},{"value":"APEC1621J Histology BioPos 3","valueDescription":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621J","ValueMeaning":{"publicId":"6360812","version":"1","preferredName":"Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621J","longName":"6360812","preferredDefinition":"APEC1621J Histology BioPos 3: Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621J","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-2897-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-28B0-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"APEC1621J Histology BioPos 2","valueDescription":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621J","ValueMeaning":{"publicId":"6360813","version":"1","preferredName":"Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621J","longName":"6360813","preferredDefinition":"APEC1621J Histology BioPos 2: Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621J","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-28BA-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-28D3-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"APEC1621J Histology BioPos 1","valueDescription":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621J","ValueMeaning":{"publicId":"6360814","version":"1","preferredName":"Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621J","longName":"6360814","preferredDefinition":"APEC1621J Histology BioPos 1: Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621J","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-28DD-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-28F6-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"APEC1621J Primary Cohort","valueDescription":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621J","ValueMeaning":{"publicId":"6360815","version":"1","preferredName":"Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621J","longName":"6360815","preferredDefinition":"APEC1621J Primary Cohort: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621J","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-2900-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-2919-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"APEC1621J Dose Finding","valueDescription":"Dose Finding: Dose finding for patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621J","ValueMeaning":{"publicId":"6360816","version":"1","preferredName":"Dose Finding: Dose finding for patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621J","longName":"6360816","preferredDefinition":"APEC1621J Dose Finding: Dose finding for patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621J","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"713A03B8-2923-25E3-E053-F662850A1967","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"713A03B8-293C-25E3-E053-F662850A1967","beginDate":"2018-07-17","endDate":null,"createdBy":"MARTINEZW","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"ADVL1217 PK Part 2","valueDescription":"Patients with newly diagnosed brainstem gliomas less than 12 years of age","ValueMeaning":{"publicId":"6401128","version":"1","preferredName":"Patients with newly diagnosed brainstem gliomas less than 12 years of age","longName":"6401128","preferredDefinition":"ADVL1217 PK Part 2: Patients with newly diagnosed brainstem gliomas less than 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"737F7D2F-BBB1-776E-E053-F662850A06C3","latestVersionIndicator":"Yes","beginDate":"2018-08-15","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-08-15","modifiedBy":"ONEDATA","dateModified":"2018-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"737F7D2F-BBCA-776E-E053-F662850A06C3","beginDate":"2018-08-15","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-08-15","modifiedBy":"ONEDATA","dateModified":"2018-08-15","deletedIndicator":"No"},{"value":"ADVL1217 PK Part 1","valueDescription":"Patients with newly diagnosed brainstem gliomas greater than or equal to 12 years of age","ValueMeaning":{"publicId":"6401129","version":"1","preferredName":"Patients with newly diagnosed brainstem gliomas greater than or equal to 12 years of age","longName":"6401129","preferredDefinition":"ADVL1217 PK Part 1: Patients with newly diagnosed brainstem gliomas greater than or equal to 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"737F7D2F-BBD4-776E-E053-F662850A06C3","latestVersionIndicator":"Yes","beginDate":"2018-08-15","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-08-15","modifiedBy":"ONEDATA","dateModified":"2018-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"737F7D2F-BBED-776E-E053-F662850A06C3","beginDate":"2018-08-15","endDate":null,"createdBy":"ARAGONP","dateCreated":"2018-08-15","modifiedBy":"ONEDATA","dateModified":"2018-08-15","deletedIndicator":"No"},{"value":"AINV18P1 Stratum 1","valueDescription":"Stratum 1: Patients with recurrent or refractory B- or T-ALL/LL","ValueMeaning":{"publicId":"6437135","version":"1","preferredName":"Stratum 1: Patients with recurrent or refractory B- or T-ALL/LL","longName":"6437135","preferredDefinition":"AINV18P1 Stratum 1: Patients with recurrent or refractory B- or T-ALL/LL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"766193F5-C3FC-1DEB-E053-F662850A264F","latestVersionIndicator":"Yes","beginDate":"2018-09-21","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-09-21","modifiedBy":"ONEDATA","dateModified":"2018-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"766193F5-C415-1DEB-E053-F662850A264F","beginDate":"2018-09-21","endDate":null,"createdBy":"SARMIENTOL","dateCreated":"2018-09-21","modifiedBy":"ONEDATA","dateModified":"2018-09-21","deletedIndicator":"No"},{"value":"ADVL1615 PK Part 2","valueDescription":"PK Part 2: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, >= 12 years of age","ValueMeaning":{"publicId":"6411446","version":"1","preferredName":"PK Part 2: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, >= 12 years of age","longName":"6411446","preferredDefinition":"ADVL1615 PK Part 2: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7422E072-5F53-21E2-E053-F662850AB17C","latestVersionIndicator":"Yes","beginDate":"2018-08-23","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-08-23","modifiedBy":"ONEDATA","dateModified":"2018-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7422E072-5F6C-21E2-E053-F662850AB17C","beginDate":"2018-08-23","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-08-23","modifiedBy":"ONEDATA","dateModified":"2018-08-23","deletedIndicator":"No"},{"value":"ADVL1615 PK Part 1","valueDescription":"PK Part 1: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, < 12 years of age","ValueMeaning":{"publicId":"6411447","version":"1","preferredName":"PK Part 1: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, < 12 years of age","longName":"6411447","preferredDefinition":"ADVL1615 PK Part 1: Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7422E072-5F76-21E2-E053-F662850AB17C","latestVersionIndicator":"Yes","beginDate":"2018-08-23","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-08-23","modifiedBy":"ONEDATA","dateModified":"2018-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7422E072-5F8F-21E2-E053-F662850AB17C","beginDate":"2018-08-23","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-08-23","modifiedBy":"ONEDATA","dateModified":"2018-08-23","deletedIndicator":"No"},{"value":"ADVL1812 Stratum Part A2","valueDescription":"ADVL1812 Part A2: Patients with relapsed or refractory AML, >= 6 months of age and < 12 months of age","ValueMeaning":{"publicId":"6548561","version":"1","preferredName":"ADVL1812 Part A2: Patients with relapsed or refractory AML, >= 6 months of age and < 12 months of age","longName":"6548561","preferredDefinition":"ADVL1812 Part A2: Patients with relapsed or refractory AML, >= 6 months of age and < 12 months of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A04935E-C073-6B8C-E053-F662850A1485","latestVersionIndicator":"Yes","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7A04935E-C08C-6B8C-E053-F662850A1485","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","deletedIndicator":"No"},{"value":"ADVL1812 Stratum Part A1","valueDescription":"ADVL1812 Part A1: Patients with relapsed or refractory AML, >= 12 months of age and <=21 years of age","ValueMeaning":{"publicId":"6548562","version":"1","preferredName":"ADVL1812 Part A1: Patients with relapsed or refractory AML, >= 12 months of age and <=21 years of age","longName":"6548562","preferredDefinition":"ADVL1812 Part A1: Patients with relapsed or refractory AML, >= 12 months of age and <=21 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7A04935E-C096-6B8C-E053-F662850A1485","latestVersionIndicator":"Yes","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7A04935E-C0AF-6B8C-E053-F662850A1485","beginDate":"2018-11-06","endDate":null,"createdBy":"BLUSTK","dateCreated":"2018-11-06","modifiedBy":"ONEDATA","dateModified":"2018-11-06","deletedIndicator":"No"},{"value":"APEC1621C Primary CNS","valueDescription":"Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C with CNS disease","ValueMeaning":{"publicId":"6719406","version":"1","preferredName":"Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C with CNS disease","longName":"6719406","preferredDefinition":"APEC1621C Primary CNS: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C with CNS disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"873BF32E-F8A3-0758-E053-F662850AE676","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"873BF32E-F8BC-0758-E053-F662850AE676","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","deletedIndicator":"No"},{"value":"APEC1621C Primary non CNS","valueDescription":"Primary non CNS: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C without CNS disease","ValueMeaning":{"publicId":"6719407","version":"1","preferredName":"Primary non CNS: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C without CNS disease","longName":"6719407","preferredDefinition":"APEC1621C Primary non CNS: Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621C without CNS disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"873BF32E-F8C6-0758-E053-F662850AE676","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"873BF32E-F8DF-0758-E053-F662850AE676","beginDate":"2019-04-23","endDate":null,"createdBy":"SHOARYAS","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","deletedIndicator":"No"},{"value":"PEPN1812 Stratum 1","valueDescription":"PEPN1812 Stratum 1: Patients with relapsed or refractory AML < 21 years of age","ValueMeaning":{"publicId":"7006934","version":"1","preferredName":"PEPN1812 Stratum 1: Patients with relapsed or refractory AML < 21 years of age","longName":"7006934","preferredDefinition":"PEPN1812 Stratum 1: Patients with relapsed or refractory AML < 21 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"952410C9-A7B6-4526-E053-F662850AB885","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"952410C9-A7CF-4526-E053-F662850AB885","beginDate":"2019-10-17","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","deletedIndicator":"No"},{"value":"PEPN1812 PK Part 1","valueDescription":"PEPN1812 PK Part 1: Patients with relapsed or refractory AML >=12 years of age","ValueMeaning":{"publicId":"7006895","version":"1","preferredName":"PEPN1812 PK Part 1: Patients with relapsed or refractory AML >=12 years of age","longName":"7006895","preferredDefinition":"PEPN1812 PK Part 1: Patients with relapsed or refractory AML >=12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9523F9F1-9668-48EC-E053-F662850AB9D7","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9523F9F1-9681-48EC-E053-F662850AB9D7","beginDate":"2019-10-17","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","deletedIndicator":"No"},{"value":"ADVL1414 Part C","valueDescription":"ADVL1414 Part C","ValueMeaning":{"publicId":"7092859","version":"1","preferredName":"ADVL1414 Part C","longName":"7092859","preferredDefinition":"Patients with recurrent/refractory high grade glioma, requiring surgical resection (excluding DIPG and disseminated tumors).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D795EB-F48F-1217-E053-F662850AB864","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D795EB-F4A8-1217-E053-F662850AB864","beginDate":"2019-12-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"ADVL1414 Part B","valueDescription":"ADVL1414 Part B","ValueMeaning":{"publicId":"7092860","version":"1","preferredName":"ADVL1414 Part B","longName":"7092860","preferredDefinition":"Patients with recurrent/refractory high grade glioma including disseminated tumors, excluding DIPG, not requiring surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D795EB-F4B2-1217-E053-F662850AB864","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D795EB-F4CB-1217-E053-F662850AB864","beginDate":"2019-12-16","endDate":null,"createdBy":"RODELAA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"ADVL18P1 Stratum 1","valueDescription":"ADVL18P1 Stratum 1: Patients with relapsed or refractory IDH2 AML greater than or equal to 24 months and less than or equal to 18 years of age with BSA less than 1.3 m2","ValueMeaning":{"publicId":"7113214","version":"1","preferredName":"ADVL18P1 Stratum 1: Patients with relapsed or refractory IDH2 AML greater than or equal to 24 months and less than or equal to 18 years of age with BSA less than 1.3 m2","longName":"7113214","preferredDefinition":"ADVL18P1 Stratum 1: Patients with relapsed or refractory IDH2 AML greater than or equal to 24 months and less than or equal to 18 years of age with BSA less than 1.3 m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A7CF47D-B77B-43FF-E053-F662850A919B","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":"20223.1.9 Added Alt VM name and def per ticket request CADSR0001884. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A7CF47D-B794-43FF-E053-F662850A919B","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"},{"value":"ADVL18P1 Stratum 2","valueDescription":"ADVL18P1 Stratum 2: Patients with relapsed or refractory IDH2 AML greater than or equal to 24 months and less than or equal to 18 years of age with BSA greater than or equal to 1.3 m2","ValueMeaning":{"publicId":"7113213","version":"1","preferredName":"ADVL18P1 Stratum 2: Patients with relapsed or refractory IDH2 AML greater than or equal to 24 months and less than or equal to 18 years of age with BSA greater than or equal to 1.3 m2","longName":"7113213","preferredDefinition":"ADVL18P1 Stratum 2: Patients with relapsed or refractory IDH2 AML greater than or equal to 24 months and less than or equal to 18 years of age with BSA greater than or equal to 1.3 m2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A7CF47D-B758-43FF-E053-F662850A919B","latestVersionIndicator":"Yes","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":"2023.1.9 Added alt VM Name and alt def per ticket request CADSR0001884. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A7CF47D-B771-43FF-E053-F662850A919B","beginDate":"2019-12-24","endDate":null,"createdBy":"BEELEST","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"},{"value":"PEPN1812 PK Part 2","valueDescription":"PEPN1812 PK Part 2: Patients with relapsed or refractory AML <12 years of age","ValueMeaning":{"publicId":"7006898","version":"1","preferredName":"PEPN1812 PK Part 2: Patients with relapsed or refractory AML <12 years of age","longName":"7006898","preferredDefinition":"PEPN1812 PK Part 2: Patients with relapsed or refractory AML <12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9523FD68-D62D-464D-E053-F662850AEA7D","latestVersionIndicator":"Yes","beginDate":"2019-10-17","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9523FD68-D646-464D-E053-F662850AEA7D","beginDate":"2019-10-17","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2019-10-17","modifiedBy":"ONEDATA","dateModified":"2019-10-17","deletedIndicator":"No"},{"value":"ADVL1712 PK Cohort 1","valueDescription":"PK Cohort 1: Patients with relapsed or refractory AML or MDS >= 12 years of age","ValueMeaning":{"publicId":"7245234","version":"1","preferredName":"PK Cohort 1: Patients with relapsed or refractory AML or MDS >= 12 years of age","longName":"7245234","preferredDefinition":"PK Cohort 1: Patients with relapsed or refractory AML or MDS >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2ED48E3-8F54-37C3-E053-F662850A1BD0","latestVersionIndicator":"Yes","beginDate":"2020-04-10","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-04-10","modifiedBy":"ONEDATA","dateModified":"2020-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2ED48E3-8F6D-37C3-E053-F662850A1BD0","beginDate":"2020-04-10","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-04-10","modifiedBy":"ONEDATA","dateModified":"2020-04-10","deletedIndicator":"No"},{"value":"APEC1621K Histology BioPos 3","valueDescription":"Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621K","ValueMeaning":{"publicId":"7169294","version":"1","preferredName":"Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621K","longName":"7169294","preferredDefinition":"Patients with relapsed or refractory, histology specific solid tumor 3, with biomarker positive MATCH to APEC1621K","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8C6503-0DDC-7369-E053-F662850A3086","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E8C6503-0DF5-7369-E053-F662850A3086","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","deletedIndicator":"No"},{"value":"APEC1621K Histology BioPos 2","valueDescription":"Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621K","ValueMeaning":{"publicId":"7169295","version":"1","preferredName":"Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621K","longName":"7169295","preferredDefinition":"Patients with relapsed or refractory, histology specific solid tumor 2, with biomarker positive MATCH to APEC1621K","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8C6503-0DFF-7369-E053-F662850A3086","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E8C6503-0E18-7369-E053-F662850A3086","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","deletedIndicator":"No"},{"value":"APEC1621K Histology BioPos 1","valueDescription":"Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621K","ValueMeaning":{"publicId":"7169296","version":"1","preferredName":"Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621K","longName":"7169296","preferredDefinition":"Patients with relapsed or refractory, histology specific solid tumor 1, biomarker positive MATCH to APEC1621K","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8C6503-0E22-7369-E053-F662850A3086","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E8C6503-0E3B-7369-E053-F662850A3086","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","deletedIndicator":"No"},{"value":"APEC1621K Primary Cohort","valueDescription":"Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621K","ValueMeaning":{"publicId":"7169297","version":"1","preferredName":"Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621K","longName":"7169297","preferredDefinition":"Patients with relapsed or refractory solid tumors, with biomarker positive MATCH to APEC1621K","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8C6503-0E45-7369-E053-F662850A3086","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E8C6503-0E5E-7369-E053-F662850A3086","beginDate":"2020-02-14","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-02-14","modifiedBy":"ONEDATA","dateModified":"2020-02-14","deletedIndicator":"No"},{"value":"ADVL1712 PK Cohort 2","valueDescription":"PK Cohort 2: Patients with relapsed or refractory AML or MDS < 12 years of age","ValueMeaning":{"publicId":"7245316","version":"1","preferredName":"PK Cohort 2: Patients with relapsed or refractory AML or MDS < 12 years of age","longName":"7245316","preferredDefinition":"PK Cohort 2: Patients with relapsed or refractory AML or MDS < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A32B3709-7B39-2C30-E053-F662850ACC31","latestVersionIndicator":"Yes","beginDate":"2020-04-13","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-04-13","modifiedBy":"ONEDATA","dateModified":"2020-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A32B3709-7B52-2C30-E053-F662850ACC31","beginDate":"2020-04-13","endDate":null,"createdBy":"RODELAA","dateCreated":"2020-04-13","modifiedBy":"ONEDATA","dateModified":"2020-04-13","deletedIndicator":"No"},{"value":"PEPN1924 Stratum 1","valueDescription":"Stratum 1: Patients with recurrent HER2+ Osteosarcoma greater than or equal to 12 years of age and less than or equal to 39 years of age","ValueMeaning":{"publicId":"7411274","version":"1","preferredName":"Stratum 1: Patients with recurrent HER2+ Osteosarcoma greater than or equal to 12 years of age and less than or equal to 39 years of age","longName":"7411274","preferredDefinition":"PEPN1924 Stratum 1: Patients with recurrent HER2+ Osteosarcoma greater than or equal to 12 years of age and less than or equal to 39 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE4509B8-0D69-3ACF-E053-4EBD850AB857","latestVersionIndicator":"Yes","beginDate":"2020-09-01","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-09-01","modifiedBy":"ONEDATA","dateModified":"2020-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE4509B8-0D82-3ACF-E053-4EBD850AB857","beginDate":"2020-09-01","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-09-01","modifiedBy":"ONEDATA","dateModified":"2020-09-01","deletedIndicator":"No"},{"value":"PEPN1924 Screening","valueDescription":"Screening: Patients with recurrent HER2+ Osteosarcoma greater than or equal to 12 years of age and less than or equal to 39 years of age","ValueMeaning":{"publicId":"7411275","version":"1","preferredName":"Screening: Patients with recurrent HER2+ Osteosarcoma greater than or equal to 12 years of age and less than or equal to 39 years of age","longName":"7411275","preferredDefinition":"PEPN1924 Screening: Patients with recurrent HER2+ Osteosarcoma greater than or equal to 12 years of age and less than or equal to 39 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE4509B8-0D8C-3ACF-E053-4EBD850AB857","latestVersionIndicator":"Yes","beginDate":"2020-09-01","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-09-01","modifiedBy":"ONEDATA","dateModified":"2020-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE4509B8-0DA5-3ACF-E053-4EBD850AB857","beginDate":"2020-09-01","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-09-01","modifiedBy":"ONEDATA","dateModified":"2020-09-01","deletedIndicator":"No"},{"value":"APEC1621M Histology BioPos 1","valueDescription":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 1, with biomarker positive MATCH to APEC1621M","ValueMeaning":{"publicId":"7334209","version":"1","preferredName":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 1, with biomarker positive MATCH to APEC1621M","longName":"7334209","preferredDefinition":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 1, with biomarker positive MATCH to APEC1621M","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A83D6238-CB00-775F-E053-4EBD850A2B85","latestVersionIndicator":"Yes","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A83D6238-CB19-775F-E053-4EBD850A2B85","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","deletedIndicator":"No"},{"value":"APEC1621M Histology BioPos 3","valueDescription":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 3, with biomarker positive MATCH to APEC1621M","ValueMeaning":{"publicId":"7334207","version":"1","preferredName":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 3, with biomarker positive MATCH to APEC1621M","longName":"7334207","preferredDefinition":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 3, with biomarker positive MATCH to APEC1621M","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A83D6238-CABA-775F-E053-4EBD850A2B85","latestVersionIndicator":"Yes","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A83D6238-CAD3-775F-E053-4EBD850A2B85","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","deletedIndicator":"No"},{"value":"APEC1621M Histology BioPos 2","valueDescription":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 2, with biomarker positive MATCH to APEC1621M","ValueMeaning":{"publicId":"7334208","version":"1","preferredName":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 2, with biomarker positive MATCH to APEC1621M","longName":"7334208","preferredDefinition":"Patients with tumors harboring HRAS genomic alterations and histology-specific group 2, with biomarker positive MATCH to APEC1621M","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A83D6238-CADD-775F-E053-4EBD850A2B85","latestVersionIndicator":"Yes","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A83D6238-CAF6-775F-E053-4EBD850A2B85","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","deletedIndicator":"No"},{"value":"APEC1621M Primary Cohort","valueDescription":"Patients with tumors harboring HRAS genomic alterations, with biomarker positive MATCH to APEC1621M","ValueMeaning":{"publicId":"7334210","version":"1","preferredName":"Patients with tumors harboring HRAS genomic alterations, with biomarker positive MATCH to APEC1621M","longName":"7334210","preferredDefinition":"Patients with tumors harboring HRAS genomic alterations, with biomarker positive MATCH to APEC1621M","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A83D6238-CB23-775F-E053-4EBD850A2B85","latestVersionIndicator":"Yes","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A83D6238-CB3C-775F-E053-4EBD850A2B85","beginDate":"2020-06-16","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-06-16","modifiedBy":"ONEDATA","dateModified":"2020-06-16","deletedIndicator":"No"},{"value":"APEC1621N Histology BioPos 3","valueDescription":"Patients with tumors harboring RET gene alterations and histology-specific group 3, with biomarker positive MATCH to APEC1621N","ValueMeaning":{"publicId":"7390700","version":"1","preferredName":"Patients with tumors harboring RET gene alterations and histology-specific group 3, with biomarker positive MATCH to APEC1621N","longName":"7390700","preferredDefinition":"Patients with tumors harboring RET gene alterations and histology-specific group 3, with biomarker positive MATCH to APEC1621N","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB51697-AC27-5DD7-E053-4EBD850A1E01","latestVersionIndicator":"Yes","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACB51697-AC40-5DD7-E053-4EBD850A1E01","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","deletedIndicator":"No"},{"value":"APEC1621N Histology BioPos 2","valueDescription":"Patients with tumors harboring RET gene alterations and histology-specific group 2, with biomarker positive MATCH to APEC1621N","ValueMeaning":{"publicId":"7390701","version":"1","preferredName":"Patients with tumors harboring RET gene alterations and histology-specific group 2, with biomarker positive MATCH to APEC1621N","longName":"7390701","preferredDefinition":"Patients with tumors harboring RET gene alterations and histology-specific group 2, with biomarker positive MATCH to APEC1621N","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB51697-AC4A-5DD7-E053-4EBD850A1E01","latestVersionIndicator":"Yes","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACB51697-AC63-5DD7-E053-4EBD850A1E01","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","deletedIndicator":"No"},{"value":"APEC1621N Histology BioPos 1","valueDescription":"Patients with tumors harboring RET gene alterations and histology-specific group 1, with biomarker positive MATCH to APEC1621N","ValueMeaning":{"publicId":"7390702","version":"1","preferredName":"Patients with tumors harboring RET gene alterations and histology-specific group 1, with biomarker positive MATCH to APEC1621N","longName":"7390702","preferredDefinition":"Patients with tumors harboring RET gene alterations and histology-specific group 1, with biomarker positive MATCH to APEC1621N","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB51697-AC6D-5DD7-E053-4EBD850A1E01","latestVersionIndicator":"Yes","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACB51697-AC86-5DD7-E053-4EBD850A1E01","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","deletedIndicator":"No"},{"value":"APEC1621N Primary Cohort","valueDescription":"Patients with tumors harboring RET gene alterations, with biomarker positive MATCH to APEC1621N","ValueMeaning":{"publicId":"7390703","version":"1","preferredName":"Patients with tumors harboring RET gene alterations, with biomarker positive MATCH to APEC1621N","longName":"7390703","preferredDefinition":"Patients with tumors harboring RET gene alterations, with biomarker positive MATCH to APEC1621N","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACB51697-AC90-5DD7-E053-4EBD850A1E01","latestVersionIndicator":"Yes","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACB51697-ACA9-5DD7-E053-4EBD850A1E01","beginDate":"2020-08-12","endDate":null,"createdBy":"LEEBUMJ","dateCreated":"2020-08-12","modifiedBy":"ONEDATA","dateModified":"2020-08-12","deletedIndicator":"No"},{"value":"PEPN2111 Part A1","valueDescription":"Part A1: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases without bone marrow involvement","ValueMeaning":{"publicId":"7671022","version":"1","preferredName":"Part A1: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases without bone marrow involvement","longName":"7671022","preferredDefinition":"PEPN2111 Part A1: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C341E480-023A-1356-E053-4EBD850A56AB","latestVersionIndicator":"Yes","beginDate":"2021-05-26","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-05-26","modifiedBy":"ONEDATA","dateModified":"2021-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C341E480-0253-1356-E053-4EBD850A56AB","beginDate":"2021-05-26","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-05-26","modifiedBy":"ONEDATA","dateModified":"2021-05-26","deletedIndicator":"No"},{"value":"ADVL1514 PK Cohort 2","valueDescription":"ADVL1514 PK Cohort 2","ValueMeaning":{"publicId":"7582432","version":"1","preferredName":"ADVL1514 PK Cohort 2","longName":"7582432","preferredDefinition":"ADVL1514 PK Cohort 2: Patients with recurrent or refractory solid tumors without bone marrow involvement including CNS tumors < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBBA01D2-29F4-0C4E-E053-4EBD850A1FEA","latestVersionIndicator":"Yes","beginDate":"2021-02-19","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBBA01D2-2A0D-0C4E-E053-4EBD850A1FEA","beginDate":"2021-02-19","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","deletedIndicator":"No"},{"value":"ADVL1514 PK Cohort 1","valueDescription":"ADVL1514 PK Cohort 1","ValueMeaning":{"publicId":"7582433","version":"1","preferredName":"ADVL1514 PK Cohort 1","longName":"7582433","preferredDefinition":"ADVL1514 PK Cohort 1: Patients with recurrent or refractory solid tumors without bone marrow involvement including CNS tumors >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBBA01D2-2A17-0C4E-E053-4EBD850A1FEA","latestVersionIndicator":"Yes","beginDate":"2021-02-19","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBBA01D2-2A30-0C4E-E053-4EBD850A1FEA","beginDate":"2021-02-19","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-19","modifiedBy":"ONEDATA","dateModified":"2021-02-19","deletedIndicator":"No"},{"value":"ADVL1414 PK Cohort 2","valueDescription":"PK Cohort 2: Patients with relapsed/refractory solid tumors without bone marrow involvement < 12 years of age","ValueMeaning":{"publicId":"7595522","version":"1","preferredName":"PK Cohort 2: Patients with relapsed/refractory solid tumors without bone marrow involvement < 12 years of age","longName":"7595522","preferredDefinition":"ADVL1414 PK Cohort 2: Patients with relapsed/refractory solid tumors without bone marrow involvement < 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5AD7FE-A47B-07E6-E053-4EBD850A69B1","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-03-12","modifiedBy":"ONEDATA","dateModified":"2021-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD5AD7FE-A494-07E6-E053-4EBD850A69B1","beginDate":"2021-03-12","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-03-12","modifiedBy":"ONEDATA","dateModified":"2021-03-12","deletedIndicator":"No"},{"value":"ADVL1414 PK Cohort 1","valueDescription":"PK Cohort 1: Patients with relapsed/refractory solid tumors without bone marrow involvement >= 12 years of age","ValueMeaning":{"publicId":"7595523","version":"1","preferredName":"PK Cohort 1: Patients with relapsed/refractory solid tumors without bone marrow involvement >= 12 years of age","longName":"7595523","preferredDefinition":"ADVL1414 PK Cohort 1: Patients with relapsed/refractory solid tumors without bone marrow involvement >= 12 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD5AD7FE-A49E-07E6-E053-4EBD850A69B1","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-03-12","modifiedBy":"ONEDATA","dateModified":"2021-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BD5AD7FE-A4B7-07E6-E053-4EBD850A69B1","beginDate":"2021-03-12","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-03-12","modifiedBy":"ONEDATA","dateModified":"2021-03-12","deletedIndicator":"No"},{"value":"ADVL18P1 Stratum 3","valueDescription":null,"ValueMeaning":{"publicId":"12309231","version":"1","preferredName":"ADVL18P1 Stratum 3: Patients with relapsed or refractory IDH2 AML >= 12 years and <= 21 years of age, who cannot swallow tablets","longName":"12309231v1.00","preferredDefinition":"ADVL18P1 Stratum 3: Patients with relapsed or refractory IDH2 AML >= 12 years and <= 21 years of age, who cannot swallow tablets","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D87A3B-0ED0-346A-E053-731AD00A721F","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D87A3B-0ED2-346A-E053-731AD00A721F","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"},{"value":"ADVL18P1 Stratum 4","valueDescription":null,"ValueMeaning":{"publicId":"12309232","version":"1","preferredName":"ADVL18P1 Stratum 4: Patients with relapsed or refractory IDH2 AML >= 12 years and <= 21 years of age who can swallow tablets","longName":"12309232v1.00","preferredDefinition":"ADVL18P1 Stratum 4: Patients with relapsed or refractory IDH2 AML >= 12 years and <= 21 years of age who can swallow tablets","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D87A3B-0ED1-346A-E053-731AD00A721F","latestVersionIndicator":"Yes","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F1D87A3B-0ED3-346A-E053-731AD00A721F","beginDate":"2023-01-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-09","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-3DF8-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"BEELEST","dateCreated":"2012-06-05","modifiedBy":"KUMMEROA","dateModified":"2023-01-09","changeDescription":"Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]}],"AlternateNames":[{"name":"Stratum_COGC","type":"USED_BY","context":"CTEP"},{"name":"Stratum_COGC","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"ADVL1312 Stratum","type":"Alternate Question Text","description":"ADVL1312 Stratum","url":null,"context":"CTEP"},{"name":"ADVL1212 Stratum","type":"Preferred Question Text","description":"ADVL1212 Stratum","url":null,"context":"COG"},{"name":"ADVL1211 Stratum","type":"Alternate Question Text","description":"ADVL1211 Stratum","url":null,"context":"CTEP"},{"name":"ADVL1214 Stratum","type":"Alternate Question Text","description":"ADVL1214 Stratum","url":null,"context":"CTEP"},{"name":"AHOD1221 Stratum","type":"Alternate Question Text","description":"AHOD1221 Stratum","url":null,"context":"CTEP"},{"name":"ADVL1213 Stratum","type":"Alternate Question Text","description":"ADVL1213 Stratum","url":null,"context":"CTEP"},{"name":"ADVL1111 Stratum","type":"Alternate Question Text","description":"ADVL1111 Stratum","url":null,"context":"CTEP"},{"name":"ADVL1217 Stratum","type":"Alternate Question Text","description":"ADVL1217 Stratum","url":null,"context":"CTEP"},{"name":"ADVL1411 Stratum","type":"Alternate Question Text","description":"ADVL1411 Stratum","url":null,"context":"CTEP"},{"name":"ADVL1314 Stratum","type":"Alternate Question Text","description":"ADVL1314 Stratum","url":null,"context":"COG"},{"name":"ADVL1315 Stratum","type":"Alternate Question Text","description":"ADVL1315 Stratum","url":null,"context":"COG"},{"name":"ADVL1416 Stratum","type":"Alternate Question Text","description":"ADVL1416 Stratum","url":null,"context":"COG"},{"name":"ADVL1412 Stratum","type":"Alternate Question Text","description":"ADVL1412 Stratum","url":null,"context":"COG"},{"name":"ADVL1414 Stratum","type":"Alternate Question Text","description":"ADVL1414 Stratum","url":null,"context":"COG"},{"name":"ADVL1611 Stratum","type":"Alternate Question Text","description":"ADVL1611 Stratum","url":null,"context":"COG"},{"name":"APEC1621 Stratum","type":"Alternate Question Text","description":"APEC1621 Stratum","url":null,"context":"COG"},{"name":"APEC1621A Stratum","type":"Alternate Question Text","description":"APEC1621A Stratum","url":null,"context":"COG"},{"name":"APEC1621D Stratum","type":"Alternate Question Text","description":"APEC1621D Stratum","url":null,"context":"COG"},{"name":"ACCL15N1CD Stratum","type":"Alternate Question Text","description":"ACCL15N1CD Stratum","url":null,"context":"COG"},{"name":"ADVL1515 Stratum","type":"Alternate Question Text","description":"ADVL1515 Stratum","url":null,"context":"COG"},{"name":"ADVL1513 Stratum","type":"Alternate Question Text","description":"ADVL1513 Stratum","url":null,"context":"COG"},{"name":"APEC1621E Stratum","type":"Alternate Question Text","description":"APEC1621E Stratum","url":null,"context":"COG"},{"name":"APEC1621C Stratum","type":"Alternate Question Text","description":"APEC1621C Stratum","url":null,"context":"COG"},{"name":"APEC1621SC Stratum","type":"Alternate Question Text","description":"APEC1621SC Stratum","url":null,"context":"COG"},{"name":"APEC1621F Stratum","type":"Alternate Question Text","description":"APEC1621F Stratum","url":null,"context":"COG"},{"name":"APEC1621G Stratum","type":"Alternate Question Text","description":"APEC1621G Stratum","url":null,"context":"COG"},{"name":"ADVL1514 Stratum","type":"Alternate Question Text","description":"ADVL1514 Stratum","url":null,"context":"COG"},{"name":"APEC1621H Stratum","type":"Alternate Question Text","description":"APEC1621H Stratum","url":null,"context":"COG"},{"name":"ACCL16N1CD Stratum","type":"Alternate Question Text","description":"ACCL16N1CD Stratum","url":null,"context":"COG"},{"name":"ADVL1615 Stratum","type":"Alternate Question Text","description":"ADVL1615 Stratum","url":null,"context":"COG"},{"name":"ADVL1614 Stratum","type":"Alternate Question Text","description":"ADVL1614 Stratum","url":null,"context":"COG"},{"name":"APEC1621I Stratum","type":"Alternate Question Text","description":"APEC1621I Stratum","url":null,"context":"COG"},{"name":"APEC1621B Stratum","type":"Alternate Question Text","description":"APEC1621B Stratum","url":null,"context":"COG"},{"name":"APEC1621J Stratum","type":"Alternate Question Text","description":"APEC1621J Stratum","url":null,"context":"COG"},{"name":"ADVL1712 Stratum","type":"Alternate Question Text","description":"ADVL1712 Stratum","url":null,"context":"COG"},{"name":"AINV18P1 Stratum","type":"Alternate Question Text","description":"AINV18P1 Stratum","url":null,"context":"COG"},{"name":"ADVL1812 Stratum","type":"Alternate Question Text","description":"ADVL1812 Stratum","url":null,"context":"COG"},{"name":"PEPN1812 Stratum","type":"Alternate Question Text","description":"PEPN1812 Stratum","url":null,"context":"COG"},{"name":"ADVL18P1 Stratum","type":"Alternate Question Text","description":"ADVL18P1 Stratum","url":null,"context":"COG"},{"name":"APEC1621K Stratum","type":"Alternate Question Text","description":"APEC1621K Stratum","url":null,"context":"COG"},{"name":"APEC1621M Stratum","type":"Alternate Question Text","description":"APEC1621M Stratum","url":null,"context":"COG"},{"name":"APEC1621N Stratum","type":"Alternate Question Text","description":"APEC1621N Stratum","url":null,"context":"COG"},{"name":"PEPN1924 Stratum","type":"Alternate Question Text","description":"PEPN1924 Stratum","url":null,"context":"COG"},{"name":"PEPN2111 Stratum","type":"Alternate Question Text","description":"PEPN2111 Stratum","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D49EF43B-5C52-686A-E040-BB89AD432CD7","latestVersionIndicator":"Yes","beginDate":"2013-01-31","endDate":null,"createdBy":"SIDDIQIF","dateCreated":"2013-01-31","modifiedBy":"LAMEMIL","dateModified":"2021-05-26","changeDescription":"Version 2 Short name changed - FAS Changed from CTEP to COG for by script Thu Jan 2 10:00:57 EST 2014","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}